WO2021185298A1 - Egfr酪氨酸激酶抑制剂及其用途 - Google Patents
Egfr酪氨酸激酶抑制剂及其用途 Download PDFInfo
- Publication number
- WO2021185298A1 WO2021185298A1 PCT/CN2021/081405 CN2021081405W WO2021185298A1 WO 2021185298 A1 WO2021185298 A1 WO 2021185298A1 CN 2021081405 W CN2021081405 W CN 2021081405W WO 2021185298 A1 WO2021185298 A1 WO 2021185298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- cancer
- compound
- alkyl
- independently selected
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 230000035772 mutation Effects 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 5
- -1 hydroxy, nitro, amino Chemical group 0.000 claims description 29
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010071990 Tyrosine kinase mutation Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 96
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 66
- 102000001301 EGF receptor Human genes 0.000 description 51
- 108060006698 EGF receptor Proteins 0.000 description 51
- 238000000034 method Methods 0.000 description 49
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 47
- 238000005481 NMR spectroscopy Methods 0.000 description 45
- 125000000623 heterocyclic group Chemical group 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 125000000217 alkyl group Chemical group 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 13
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical group OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 11
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 125000006413 ring segment Chemical group 0.000 description 11
- 125000003367 polycyclic group Chemical group 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 7
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 7
- 102220004843 rs397516975 Human genes 0.000 description 7
- 102220014441 rs397517109 Human genes 0.000 description 7
- 102220055958 rs727504263 Human genes 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 0 N#CC1CC=C(C*I)CC1 Chemical compound N#CC1CC=C(C*I)CC1 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- SADXACCFNXBCFY-IYNHSRRRSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\[C@@H]3N(CCC3)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 description 4
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical group CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 4
- 229950009876 poziotinib Drugs 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 229940075576 pyrotinib Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- AVAWMINJNRAQFS-ZCFIWIBFSA-N (3r)-n,n-dimethylpyrrolidin-3-amine Chemical group CN(C)[C@@H]1CCNC1 AVAWMINJNRAQFS-ZCFIWIBFSA-N 0.000 description 3
- WSLRIJFIFPFAFB-UHFFFAOYSA-N 2-(4,4-difluorocyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical group O1C(C)(C)C(C)(C)OB1C1=CCC(F)(F)CC1 WSLRIJFIFPFAFB-UHFFFAOYSA-N 0.000 description 3
- WFZUBZAEFXETBF-UHFFFAOYSA-N 2-fluoro-3-methylaniline Chemical group CC1=CC=CC(N)=C1F WFZUBZAEFXETBF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229910020008 S(O) Inorganic materials 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical group ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229960003278 osimertinib Drugs 0.000 description 3
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical group COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QZUXMXZNVAJNSE-UHFFFAOYSA-N 2-fluoro-5-methylaniline Chemical group CC1=CC=C(F)C(N)=C1 QZUXMXZNVAJNSE-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- SUWHIYNLICSLAG-UHFFFAOYSA-N CC(C=C1)=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(C=C2)=CC=C2F)=C1F Chemical compound CC(C=C1)=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(C=C2)=CC=C2F)=C1F SUWHIYNLICSLAG-UHFFFAOYSA-N 0.000 description 2
- CRGPCELRCNEZMV-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=CC=C2)=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=CC=C2)=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O CRGPCELRCNEZMV-UHFFFAOYSA-N 0.000 description 2
- BNJMNJKXONWBMX-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=CN2C)=CC2=O)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=CN2C)=CC2=O)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O BNJMNJKXONWBMX-UHFFFAOYSA-N 0.000 description 2
- IWNBQXFSYAIRCJ-SSDOTTSWSA-N CN(C)[C@H]1CN(C)CC1 Chemical compound CN(C)[C@H]1CN(C)CC1 IWNBQXFSYAIRCJ-SSDOTTSWSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methyl-N-phenylamine Natural products CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- LLHICPSCVFRWDT-UHFFFAOYSA-N S-(5-acetamido-2-hydroxyphenyl)cysteine Chemical group CC(=O)NC1=CC=C(O)C(SCC(N)C(O)=O)=C1 LLHICPSCVFRWDT-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- QCIFLGSATTWUQJ-UHFFFAOYSA-N n,4-dimethylaniline Chemical group CNC1=CC=C(C)C=C1 QCIFLGSATTWUQJ-UHFFFAOYSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- QIFVXSLMFCRLCB-UHFFFAOYSA-N (1-methyl-2-oxopyridin-4-yl)boronic acid Chemical group CN1C=CC(B(O)O)=CC1=O QIFVXSLMFCRLCB-UHFFFAOYSA-N 0.000 description 1
- QEAXTGJPPXLMPC-UHFFFAOYSA-N (1-methyl-6-oxopyridin-3-yl)boronic acid Chemical group CN1C=C(B(O)O)C=CC1=O QEAXTGJPPXLMPC-UHFFFAOYSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical group COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- WJDZZXIDQYKVDG-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)boronic acid Chemical group OB(O)C1=CC=C(F)C(Cl)=C1 WJDZZXIDQYKVDG-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical group COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- UBVNILVKTTUUJH-UHFFFAOYSA-N (4,4-difluorocyclohexen-1-yl)boronic acid Chemical group OB(O)C1=CCC(F)(F)CC1 UBVNILVKTTUUJH-UHFFFAOYSA-N 0.000 description 1
- CEBAHYWORUOILU-ZFJHNFROSA-N (4-cyanophenyl)boronic acid Chemical group OB(O)[13C]1=[13CH][13CH]=[13C](C#N)[13CH]=[13CH]1 CEBAHYWORUOILU-ZFJHNFROSA-N 0.000 description 1
- WRQNDLDUNQMTCL-UHFFFAOYSA-N (4-ethoxyphenyl)boronic acid Chemical group CCOC1=CC=C(B(O)O)C=C1 WRQNDLDUNQMTCL-UHFFFAOYSA-N 0.000 description 1
- IQMLIVUHMSIOQP-UHFFFAOYSA-N (4-fluoro-2-methylphenyl)boronic acid Chemical group CC1=CC(F)=CC=C1B(O)O IQMLIVUHMSIOQP-UHFFFAOYSA-N 0.000 description 1
- JCIJCHSRVPSOML-UHFFFAOYSA-N (4-fluoro-3-methylphenyl)boronic acid Chemical group CC1=CC(B(O)O)=CC=C1F JCIJCHSRVPSOML-UHFFFAOYSA-N 0.000 description 1
- WLCGYIWOKVWFLB-UHFFFAOYSA-N (4-propylphenyl)boronic acid Chemical group CCCC1=CC=C(B(O)O)C=C1 WLCGYIWOKVWFLB-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- HLXOVAMYQUFLPE-UHFFFAOYSA-N 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group CN1N=CC=C1B1OC(C)(C)C(C)(C)O1 HLXOVAMYQUFLPE-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical group C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- PUJKAJRQPDUAFS-UHFFFAOYSA-N 2-(4-methoxycyclohexen-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical group C1C(OC)CCC(B2OC(C)(C)C(C)(C)O2)=C1 PUJKAJRQPDUAFS-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQEXBVHABAJPHJ-UHFFFAOYSA-N 2-fluoro-4-methylaniline Chemical group CC1=CC=C(N)C(F)=C1 ZQEXBVHABAJPHJ-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- VGPRNGGSKJHOFE-UHFFFAOYSA-N 2-methylpyrimidin-5-amine Chemical group CC1=NC=C(N)C=N1 VGPRNGGSKJHOFE-UHFFFAOYSA-N 0.000 description 1
- XWBTZHDDWRNOQH-UHFFFAOYSA-N 3-chloro-2-fluoroaniline Chemical group NC1=CC=CC(Cl)=C1F XWBTZHDDWRNOQH-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical group NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- ZNQOALAKPLGUPH-UHFFFAOYSA-N 5-methylpyrazin-2-amine Chemical group CC1=CN=C(N)C=N1 ZNQOALAKPLGUPH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- BIBDPNJFOIMTGY-UHFFFAOYSA-N CC(C=C(C=C1)C2=CN=C(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)N=C2NC(C=CC=C2)=C2F)=C1F Chemical compound CC(C=C(C=C1)C2=CN=C(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)N=C2NC(C=CC=C2)=C2F)=C1F BIBDPNJFOIMTGY-UHFFFAOYSA-N 0.000 description 1
- DWPVDTZTUTUVGV-UHFFFAOYSA-N CC(C=C(C=C1)F)=C1C1=CN=C(NC(C(OC)=C2)=CC(NC(C=C)=O)=C2N(C)CCN(C)C)N=C1NC(C=CC=C1)=C1F Chemical compound CC(C=C(C=C1)F)=C1C1=CN=C(NC(C(OC)=C2)=CC(NC(C=C)=O)=C2N(C)CCN(C)C)N=C1NC(C=CC=C1)=C1F DWPVDTZTUTUVGV-UHFFFAOYSA-N 0.000 description 1
- LHRJVQXGMKTZLU-UHFFFAOYSA-N CC(C=C1)=CC(F)=C1NC1=NC(NC(C(OC)=C2)=CC(NC(C=C)=O)=C2N(C)CCN(C)C)=NC=C1C(C=C1)=CC=C1F Chemical compound CC(C=C1)=CC(F)=C1NC1=NC(NC(C(OC)=C2)=CC(NC(C=C)=O)=C2N(C)CCN(C)C)=NC=C1C(C=C1)=CC=C1F LHRJVQXGMKTZLU-UHFFFAOYSA-N 0.000 description 1
- VNHAJZNABIQLBA-UHFFFAOYSA-N CC(C=C1)=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(CC2)=CCC2(F)F)=C1F Chemical compound CC(C=C1)=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(CC2)=CCC2(F)F)=C1F VNHAJZNABIQLBA-UHFFFAOYSA-N 0.000 description 1
- XQPXGJVRVNZXHQ-UHFFFAOYSA-N CC(N=C1)=CN=C1NC1=NC(NC(C(OC)=C2)=CC(NC(C=C)=O)=C2N(C)CCN(C)C)=NC=C1C(C=C1)=CC=C1F Chemical compound CC(N=C1)=CN=C1NC1=NC(NC(C(OC)=C2)=CC(NC(C=C)=O)=C2N(C)CCN(C)C)=NC=C1C(C=C1)=CC=C1F XQPXGJVRVNZXHQ-UHFFFAOYSA-N 0.000 description 1
- RAIIYANKUSTSMB-UHFFFAOYSA-N CC1=CC=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(C=C2)=CC=C2F)=C1F Chemical compound CC1=CC=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(C=C2)=CC=C2F)=C1F RAIIYANKUSTSMB-UHFFFAOYSA-N 0.000 description 1
- GBUHQECBXYSHQA-UHFFFAOYSA-N CC1=CC=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(C=C2)=CC=C2OC)=C1F Chemical compound CC1=CC=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(C=C2)=CC=C2OC)=C1F GBUHQECBXYSHQA-UHFFFAOYSA-N 0.000 description 1
- VBMXGFLRZKFZDM-UHFFFAOYSA-N CC1=CC=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(CC2)=CCC2(F)F)=C1F Chemical compound CC1=CC=CC(NC2=NC(NC(C(OC)=C3)=CC(NC(C=C)=O)=C3N(C)CCN(C)C)=NC=C2C(CC2)=CCC2(F)F)=C1F VBMXGFLRZKFZDM-UHFFFAOYSA-N 0.000 description 1
- UPQJPVGJQKTFHJ-UHFFFAOYSA-N CCC(C(C=C1)=CN(C)C1=O)O Chemical compound CCC(C(C=C1)=CN(C)C1=O)O UPQJPVGJQKTFHJ-UHFFFAOYSA-N 0.000 description 1
- 229940126010 CLN-081 Drugs 0.000 description 1
- VPFIUUOJUJHRPE-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O VPFIUUOJUJHRPE-UHFFFAOYSA-N 0.000 description 1
- STWQNPCIKPGFNB-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2OC)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2OC)=N1)=C1)OC)=C1NC(C=C)=O STWQNPCIKPGFNB-UHFFFAOYSA-N 0.000 description 1
- UJVNSPNIXXUJAI-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2P(C)(C)=O)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2P(C)(C)=O)=N1)=C1)OC)=C1NC(C=C)=O UJVNSPNIXXUJAI-UHFFFAOYSA-N 0.000 description 1
- AIXRKPGGLVXXKM-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2Cl)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2Cl)=C2F)=N1)=C1)OC)=C1NC(C=C)=O AIXRKPGGLVXXKM-UHFFFAOYSA-N 0.000 description 1
- GUBOTVDBYWLSMA-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CN(C)C2=O)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(C=C2)=CN(C)C2=O)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O GUBOTVDBYWLSMA-UHFFFAOYSA-N 0.000 description 1
- CWEGNSKXORETDU-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(CC2)=CCC2(F)F)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C(F)=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(CC2)=CCC2(F)F)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C(F)=C)=O CWEGNSKXORETDU-UHFFFAOYSA-N 0.000 description 1
- ROPXCXIRTHQQGQ-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(CC2)=CCC2(F)F)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(CC2)=CCC2(F)F)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O ROPXCXIRTHQQGQ-UHFFFAOYSA-N 0.000 description 1
- UFQQZSGTGASEKM-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(CC2)=CCC2C#N)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C(CC2)=CCC2C#N)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O UFQQZSGTGASEKM-UHFFFAOYSA-N 0.000 description 1
- PRZJYVXPXPPRAL-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC(OC)=CC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC(OC)=CC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O PRZJYVXPXPPRAL-UHFFFAOYSA-N 0.000 description 1
- KVFRJXWDRIMZRL-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC=C(C(F)(F)F)C=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC=C(C(F)(F)F)C=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O KVFRJXWDRIMZRL-UHFFFAOYSA-N 0.000 description 1
- FYZLEKSQRCDREZ-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC=CN=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC=CN=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O FYZLEKSQRCDREZ-UHFFFAOYSA-N 0.000 description 1
- LYCRQVXGCWDDTG-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC=NC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CC=NC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O LYCRQVXGCWDDTG-UHFFFAOYSA-N 0.000 description 1
- ABDBPZBHKZOSBK-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CN=CS2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CN=CS2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O ABDBPZBHKZOSBK-UHFFFAOYSA-N 0.000 description 1
- HUBBYKLEPARQSU-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=COC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=COC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O HUBBYKLEPARQSU-UHFFFAOYSA-N 0.000 description 1
- XELTVZUYCOUSEG-UHFFFAOYSA-N CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CSC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)CCN(C)C(C=C(C(NC1=NC=C(C2=CSC=C2)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O XELTVZUYCOUSEG-UHFFFAOYSA-N 0.000 description 1
- KGLVKGGTKOTDJW-JOCHJYFZSA-N CN(C)[C@H](CC1)CN1C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)[C@H](CC1)CN1C(C=C(C(NC1=NC=C(C(C=C2)=CC=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O KGLVKGGTKOTDJW-JOCHJYFZSA-N 0.000 description 1
- ZLCNFPWSFKJBHN-OAQYLSRUSA-N CN(C)[C@H](CC1)CN1C(C=C(C(NC1=NC=C(C(C=N2)=CC=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O Chemical compound CN(C)[C@H](CC1)CN1C(C=C(C(NC1=NC=C(C(C=N2)=CC=C2OC)C(NC(C=CC=C2)=C2F)=N1)=C1)OC)=C1NC(C=C)=O ZLCNFPWSFKJBHN-OAQYLSRUSA-N 0.000 description 1
- YZJCNADFGXFEHX-UHFFFAOYSA-N CN(C=CC(I)=C1)C1=O Chemical compound CN(C=CC(I)=C1)C1=O YZJCNADFGXFEHX-UHFFFAOYSA-N 0.000 description 1
- LDVAIJZDACHGML-UHFFFAOYSA-N CNc(cccc1)c1F Chemical compound CNc(cccc1)c1F LDVAIJZDACHGML-UHFFFAOYSA-N 0.000 description 1
- KNZWULOUXYKBLH-UHFFFAOYSA-N CNc(cccc1)c1OC Chemical compound CNc(cccc1)c1OC KNZWULOUXYKBLH-UHFFFAOYSA-N 0.000 description 1
- CJGFTBAVKRBMRE-UHFFFAOYSA-N CNc(cccc1Cl)c1F Chemical compound CNc(cccc1Cl)c1F CJGFTBAVKRBMRE-UHFFFAOYSA-N 0.000 description 1
- FHYDHJXZZQCXOX-UHFFFAOYSA-N CNc1cc(F)ccc1 Chemical compound CNc1cc(F)ccc1 FHYDHJXZZQCXOX-UHFFFAOYSA-N 0.000 description 1
- NTXRNCUPGYOZCN-UHFFFAOYSA-N COc(nc1)ccc1I Chemical compound COc(nc1)ccc1I NTXRNCUPGYOZCN-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VKVFDPQDGZSLJK-UHFFFAOYSA-N Cc(cc1)c[n]2c1ncc2 Chemical compound Cc(cc1)c[n]2c1ncc2 VKVFDPQDGZSLJK-UHFFFAOYSA-N 0.000 description 1
- KICWBKWNKZINLP-UHFFFAOYSA-N Cc(cc1)cc(F)c1NC Chemical compound Cc(cc1)cc(F)c1NC KICWBKWNKZINLP-UHFFFAOYSA-N 0.000 description 1
- GYVGXEWAOAAJEU-UHFFFAOYSA-N Cc(cc1)ccc1N(C)C Chemical compound Cc(cc1)ccc1N(C)C GYVGXEWAOAAJEU-UHFFFAOYSA-N 0.000 description 1
- PLCVAKVSMLYGCD-UHFFFAOYSA-N Cc(nc1)cnc1NC Chemical compound Cc(nc1)cnc1NC PLCVAKVSMLYGCD-UHFFFAOYSA-N 0.000 description 1
- FENSBHAUEUGKRF-UHFFFAOYSA-N Cc(nc1)ncc1NC Chemical compound Cc(nc1)ncc1NC FENSBHAUEUGKRF-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- LXPYXLTZQOLCIZ-UHFFFAOYSA-N Ic1cc2ncc[n]2cc1 Chemical compound Ic1cc2ncc[n]2cc1 LXPYXLTZQOLCIZ-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- MKCYPWYURWOKST-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-INIZCTEOSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical group OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- STSBIYSZXHSXHH-UHFFFAOYSA-N but-2-ynamide Chemical compound CC#CC(N)=O STSBIYSZXHSXHH-UHFFFAOYSA-N 0.000 description 1
- UFBHSXXPAZMVSI-UHFFFAOYSA-N but-2-ynoyl chloride Chemical group CC#CC(Cl)=O UFBHSXXPAZMVSI-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical group C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 231100000294 dose-dependent toxicity Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940121645 first-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical group OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- IPJIKGJKMCILGV-UHFFFAOYSA-N imidazo[1,2-a]pyridin-6-ylboronic acid Chemical group C1=C(B(O)O)C=CC2=NC=CN21 IPJIKGJKMCILGV-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical group COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000552 p-cresyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1O*)C([H])([H])[H] 0.000 description 1
- IWDCLRJOBJJRNH-UHFFFAOYSA-N para-hydroxytoluene Natural products CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical group OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical group OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229950009855 rociletinib Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical group OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
Definitions
- This application belongs to the field of chemistry and medicine, and specifically relates to an EGFR tyrosine kinase inhibitor and its use.
- Lung cancer is one of the most common malignant tumors in the world. Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC includes squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma and large cell carcinoma. Compared with SCLC, NSCLC cancer cells grow and divide more slowly, and spread and metastasize relatively late. NSCLC accounts for about 80% of all lung cancers, and the prognosis is poor. About 75% of patients are in the advanced stage when they are discovered.
- SCLC small cell lung cancer
- NSCLC non-small cell lung cancer
- epidermal growth factor receptor EGFR
- NSCLC Oncotarget.2016Jul 5; 7(27): 41691-41702
- EGFR is a member of the epidermal growth factor receptor (HER) family, which is composed of EGFR (Erb-B1), Erb-B2 (HER-2/neu), Erb-B3 and Erb-B4.
- EGFR is a glycoprotein. It is a receptor for epidermal growth factor (EGF) cell proliferation and signal transduction. It is a tyrosine kinase receptor with a permeable cell membrane and located on the surface of the cell membrane (Clin Cancer Res; 21(3) February 1, 2015, 526-533).
- EGFR is not only overexpressed, but also has abnormal activation mutations in its tyrosine kinase structure region that do not depend on ligand binding.
- the most common kinase activity mutations are EGFR (Exon 19 del E746-A750) and EGFR (Exon 21 L858R), the first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that has been marketed and gefitinib (gefitinib) And erlotinib (erlotinib) has been approved for the treatment of these two mutations, but the first generation of EGFR-TKI developed drug resistance during the treatment process, and the generation of drug resistance was replaced with the threonine at position 790 of EGFR It is related to the secondary mutation of methionine (T790M).
- the second-generation non-reversible covalent inhibitors such as Afatinib
- the reasons are It is more active against wild-type EGFR than inhibiting EGFR (delE746-A750/T790M) and EGFR (L858R/T790M) resistant mutants, thus exhibiting dose-dependent toxicity (Biologics, 2014, 8:183-192) , Unable to obtain an effective treatment window. Therefore, the third-generation EGFR-TKI has been developed, such as AZD9291, CO-1686 and HM61713.
- the third-generation EGFR-TKI is a tyrosine kinase inhibitor with specific selectivity. Compared with the first and second generation of EGFR-TKI, the third generation of EGFR-TKI reduces the inhibition of wild-type EGFR, reduces clinical toxic side effects, and can use higher clinical doses to obtain better curative effects . (J Clin Oncol 2014; 32: abstr 8009; J Clin Oncol 2014; 32: abstr 8010).
- EGFR exon20 ins Another type of EGFR mutation that is abnormally activated and induces cancer is the exon 20 insertion mutation (EGFR exon20 ins).
- EGFR exon20 ins Another type of EGFR mutation that is abnormally activated and induces cancer.
- This application discloses a class of compounds that can be used as EGFR protein kinase inhibitors and their use in the preparation of drugs for the prevention or treatment of EGFR-related diseases.
- this application provides a compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof:
- Z 1 is -NH-, -N(CH 3 )-, -O- or -S-;
- Z 2 , Z 3 , Z 4 , and Z 5 are each independently selected from C or N;
- Ring A is selected from aryl, heteroaryl, partially unsaturated cycloalkyl or partially unsaturated heterocycloalkyl;
- Ring B is heterocycloalkyl or not present
- Each R 1 is independently selected from hydrogen, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, halogen, hydroxy, nitro, amino, cyano, alkoxy or Two adjacent R 1 can form an aryl group or a heteroaryl group together with the atoms to which they are connected;
- Each R 2 is independently selected from hydrogen, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, halogen, hydroxy, nitro, amino, cyano, carbonyl or alkoxy;
- R 3 is selected from hydrogen, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, halogen, hydroxy, nitro, amino, cyano or alkoxy;
- R 4 is selected from
- G is selected from and
- n and n are independently selected from 1, 2 or 3, respectively.
- formula (I) is formula (Ia):
- Z 1 is -NH-, -N(CH 3 )-, -O- or -S-;
- Z 2 , Z 3 , Z 4 , and Z 5 are each independently selected from C or N;
- Ring A is selected from aryl, heteroaryl, partially unsaturated cycloalkyl or partially unsaturated heterocycloalkyl;
- Ring B is heterocycloalkyl or not present
- Each R 1 is independently selected from hydrogen, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, halogen, hydroxy, nitro, amino, cyano, alkoxy or Two adjacent R 1 can form an aryl group or a heteroaryl group together with the atoms to which they are connected;
- Each R 2 is independently selected from hydrogen, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl, halogen, hydroxy, nitro, amino, cyano, carbonyl or alkoxy;
- R 4 is selected from
- G is selected from and
- n and n are independently selected from 1, 2 or 3, respectively.
- Z 1 is -NH-, -N(CH 3 )- or -O-;
- Z 2 , Z 3 , Z 4 , and Z 5 are each independently selected from C or N, and Z 3 and Z 4 are not N at the same time;
- Each R 1 is independently selected from hydrogen, C 1 -C 3 alkyl, halogen or Two adjacent R 1 can form a benzene ring with the atoms to which they are connected;
- Each R 2 is independently selected from hydrogen, C 1 -C 3 alkyl, halo C 1 -C 3 alkyl, halogen, cyano, carbonyl, or alkoxy;
- n and n are independently selected from 1 or 2 respectively.
- formula (I) is selected from the following compounds:
- the aforementioned compounds can be used to prepare drugs for the prevention or treatment of receptor tyrosine kinase mutations, especially EGFR mutation-related diseases;
- the EGFR mutation-related diseases are cancers, especially related cancers that have mutations in the exon 20 domain of EGFR ,
- this application also provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or isomer thereof; and a pharmaceutically acceptable carrier or excipient .
- the pharmaceutically acceptable carrier or excipient may include any conventional pharmaceutical carrier or excipient. Suitable pharmaceutical carriers include inert diluents or fillers, water, and various organic solvents such as hydrates and solvents. If necessary, the pharmaceutical composition may contain additional ingredients such as flavoring agents, binders, excipients, and the like.
- the aforementioned pharmaceutical composition may also contain one or more other anti-cancer drugs, and the anti-cancer drugs are small molecule drugs, monoclonal antibodies or fusion protein drugs.
- the compound with EGFR tyrosine kinase inhibitory activity provided in this application has a strong inhibitory ability on EGFR (D770_N771insNPG) insertion mutation kinase activity.
- the inhibition of the proliferation ability of wild-type EGFR high-expressing mouse primary B cells (BaF3) is much lower than that of Poziotinib and Ref-1, which are currently in clinical research. At the same time, it can effectively inhibit BaF3 with high expression of EGFR exon20 insertion mutation. Cell Proliferation. Compared with a single mutant EGFR that highly expresses tumor cell proliferation inhibitory activity, the selective inhibitory activity of mutant cells relative to wild cells is a more important and critical indicator as a clinical treatment window.
- the compounds provided in this application can be used in higher doses in clinical applications without causing obvious toxicity, greatly improving the curative effect, and obtaining better prognostic effects. And it has a good inhibitory effect on the abnormal proliferation of tumor cells with high expression of common EGFR mutations, EGFR (delE746-A750), and Her2 insertion mutations.
- isomer includes enantiomeric forms, diastereomeric forms, and geometric (or conformational) isomeric forms of a given structure.
- this application includes the R and S configurations of each asymmetric center, Z and E double bond isomers, Z and E conformational isomers, single stereochemical isomers and enantiomers, diastereomers Isomers and geometric (or conformational) isomer mixtures.
- Suitable acid addition salts are formed from acids, which form non-toxic salts, such as hydrochloride/chloride.
- Suitable base salts are formed from bases, which form non-toxic salts such as calcium and sodium salts. It is also possible to form half salts of acids and bases, such as hemisulfate and hemicalcium salts.
- terapéuticaally effective amount refers to the following amount of the compound of the present application, which (i) treats a specific disease, disorder, or disorder; (ii) reduces, alleviates, or eliminates one or more symptoms of a specific disease, disorder, or disorder Or (iii) to prevent or delay the onset of one or more symptoms of the specific disease, condition or disorder described in this application.
- pharmaceutically acceptable carrier or excipient refers to a non-toxic carrier, excipient or vehicle that does not destroy the pharmacological activity of the compound formulated with it.
- alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably containing 1 to 6 carbon atoms Atom of the alkyl group.
- Non-limiting examples of lower alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl Group, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methyl Butyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-Dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-Dimethylbutyl and so on.
- alkenyl refers to an aliphatic hydrocarbon having at least one carbon-carbon double bond, including straight and branched chains having at least one carbon-carbon double bond. In some embodiments, alkenyl groups have 2 to 20 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, 3 to 6 carbon atoms, or 2 to 4 carbon atoms.
- C 2-6 alkenyl includes linear or branched unsaturated groups of 2 to 6 carbon atoms (having at least one carbon-carbon double bond), including but not limited to vinyl, 1-propenyl , 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, etc.
- alkynyl refers to an aliphatic hydrocarbon having at least one carbon-carbon triple bond, including straight and branched chains having at least one carbon-carbon triple bond.
- an alkynyl group has 2 to 20, 2 to 10, 2 to 6, or 3 to 6 carbon atoms.
- C 2-6 alkynyl includes straight or branched chain hydrocarbon alkynyl groups having 2 to 6 carbon atoms as defined above.
- alkoxy refers to -O- (alkyl) and -O- (unsubstituted cycloalkyl), where alkyl is as defined above.
- alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent.
- the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 Carbon atoms (e.g. 3, 4, 5 or 6 carbon atoms), most preferably 5 to 6 carbon atoms.
- Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatriene Groups, cyclooctyl, etc.; polycyclic cycloalkyls include spiro, fused, and bridged cycloalkyls.
- spirocycloalkyl refers to a polycyclic group that shares one carbon atom (called a spiro atom) between 5- to 20-membered monocyclic rings. It may contain one or more double bonds, but none of the rings have complete conjugation. ⁇ electronic system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan (for example, 7, 8, 9 or 10 yuan).
- the spirocycloalkyl group is classified into a single spirocycloalkyl group, a bispirocycloalkyl group or a polyspirocycloalkyl group, preferably a single spirocycloalkyl group and a bispirocycloalkyl group. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered monospirocycloalkyl.
- fused cycloalkyl refers to a 5- to 20-membered all-carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or Multiple double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
- the number of constituent rings it can be classified into bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyls, preferably bicyclic or tricyclic, and more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic alkyl.
- bridged cycloalkyl refers to a 5- to 20-membered, all-carbon polycyclic group with any two rings sharing two carbon atoms that are not directly connected. It may contain one or more double bonds, but no ring has a complete Conjugated ⁇ electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of constituent rings, it can be classified into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyls, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic.
- heterocyclyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (where m is an integer of 0 to 2) heteroatoms, but does not include the ring part of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. It preferably contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; most preferably contains 3 to 8 ring atoms, of which 1 to 3 are heteroatoms; most preferably contains 5 to 6 ring atoms, of which 1 to 2 or 1 to 3 are heteroatoms.
- Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrazolyl, Hydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc., preferably tetrahydropyranyl, piperidinyl, and pyrrolidinyl.
- Polycyclic heterocyclic groups include spiro heterocyclic groups, fused heterocyclic groups, and bridged heterocyclic groups.
- spiroheterocyclic group refers to a polycyclic heterocyclic group that shares one atom (called a spiro atom) between 5- to 20-membered monocyclic rings, in which one or more ring atoms are selected from nitrogen, oxygen or S(O ) Heteroatoms of m (where m is an integer of 0 to 2), and the remaining ring atoms are carbon. It can contain one or more double bonds, but none of the rings have a fully conjugated ⁇ -electron system. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
- the spiro heterocyclic group is classified into a single spiro heterocyclic group, a dispiro heterocyclic group or a polyspiro heterocyclic group, preferably a single spiro heterocyclic group and a dispiro heterocyclic group. More preferably, it is a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered monospiro heterocyclic group.
- fused heterocyclic group refers to a 5- to 20-membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system.
- One or more rings may contain one or more Double bond, but none of the rings have a fully conjugated ⁇ -electron system, where one or more of the ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)m (where m is an integer from 0 to 2), and the rest of the ring
- the atom is carbon. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
- the number of constituent rings it can be classified into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups, preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic group.
- bridged heterocyclic group refers to a 5- to 14-membered polycyclic heterocyclic group with any two rings sharing two atoms that are not directly connected. It may contain one or more double bonds, but none of the rings has a complete common A conjugated ⁇ -electron system in which one or more ring atoms are heteroatoms selected from nitrogen, oxygen or S(O)m (where m is an integer of 0 to 2), and the remaining ring atoms are carbon. It is preferably 6 to 14 yuan, more preferably 7 to 10 yuan.
- the number of constituent rings it can be classified into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic.
- the heterocyclic group includes the heterocyclic group as described above (including monocyclic, spiro heterocyclic, fused heterocyclic, and bridged heterocyclic ring) fused on an aryl, heteroaryl or cycloalkyl ring, which is combined with the parent structure
- the rings connected together are heterocyclic groups, non-limiting examples of which include:
- aryl refers to a 6 to 14-membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) with a conjugated ⁇ -electron system, preferably 6 to 10 members, such as benzene Base and naphthyl.
- heteroaryl refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, where the heteroatoms are selected from oxygen, sulfur, and nitrogen.
- Heteroaryl groups are preferably 5 to 10 members, containing 1 to 3 heteroatoms; more preferably 5 or 6 members, containing 1 to 2 heteroatoms; preferably, for example, imidazolyl, furyl, thienyl, thiazolyl, pyridine Azolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl and pyridazinyl, etc.
- the heteroaryl group includes the heteroaryl group as described above fused on an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples thereof include :
- hydroxyalkyl refers to an alkyl group substituted with a hydroxy group, where the alkyl group is as defined above.
- haloalkyl refers to an alkyl group substituted with one or more halogens, where the alkyl group is as defined above.
- haloalkoxy refers to an alkoxy group substituted with one or more halogens, where alkoxy is as defined above.
- deuterated alkyl refers to an alkyl group substituted with one or more deuterium atoms, where the alkyl group is as defined above.
- deuterated alkoxy refers to an alkoxy group substituted with one or more deuterium atoms, where the alkoxy group is as defined above.
- cycloalkylalkyl refers to an alkyl group substituted with one or more cycloalkyl groups, wherein cycloalkyl and alkyl are as defined above.
- cycloalkyloxy refers to -O-cycloalkyl, where cycloalkyl is as defined above.
- heterocyclylalkyl refers to an alkyl group substituted with one or more heterocyclic groups, wherein heterocyclyl and alkyl are as defined above.
- arylalkyl refers to an alkyl group substituted with one or more aryl groups, where aryl and alkyl are as defined above.
- hydroxy refers to the -OH group.
- halogen refers to fluorine, chlorine, bromine or iodine.
- amino refers to -NH 2 .
- cyano refers to -CN.
- nitro refers to -NO 2 .
- Dissolve compound 1.9 (2.140g, 4.03mmol, 1eq.) in DCM (20mL), reduce to -20°C in a dry ice ethanol bath, add triethylamine (814.66mg, 8.05mmol, 2eq.), compound 1.10 (364.33mg) , 4.03mmol, 1eq.), react for 10min, add water (20mL) to the system, extract with DCM (100mL), separate the layers, wash the organic phase with saturated aqueous NaCl once, separate the layers, and dry the organic phase with anhydrous magnesium sulfate.
- step 2 Using a method similar to Example 1, the compound 1.4 of step 2 was replaced with (4,4-difluorocyclohex-1-en-1-yl)boronic acid to obtain the title compound.
- 1 H NMR 400MHz, DMSO-d6) (ppm): 10.05 (s, 1H), 8.49 (s, 1H), 7.94 (s, 2H), 7.71-7.85 (m, 2H), 7.16-7.21 (m.
- step 1 Using a method similar to Example 1, the compound 1.2 of step 1 was replaced with 2-fluoro-3-methylaniline, and the compound 1.4 of step 2 was replaced with 4,4-difluorocyclohex-1-enylboronic acid pinacol Ester to give the title compound.
- step 1 Using the method similar to Example 1, the compound 1.2 of step 1 was replaced with 2-fluoro-5-methylaniline, and the compound 1.4 of step 2 was replaced with 4,4-difluorocyclohex-1-enylboronic acid pinacol Ester to give the title compound.
- step 2 Using a method similar to Example 1, the compound 1.4 in step 2 was replaced with 4,4-difluorocyclohex-1-enyl boronic acid pinacol ester, and the N,N,N'-trimethylethylene in step 4 The amine was replaced with (3R)-(+)-3-dimethylaminopyrrolidine to give the title compound.
- step 2 Using a similar method to Example 1, the compound 1.4 of step 2 was replaced with 4,4-difluorocyclohex-1-enylboronic acid pinacol ester, and the compound of step 6 acryloyl chloride was replaced with 2-fluoroacryloyl chloride, The title compound is obtained.
- step 2 Using a similar method to Example 1, the compound 1.4 of step 2 was replaced with 2-methoxy-5-pyridineboronic acid, and the N,N,N'-trimethylethylenediamine of step 4 was replaced with (3R)- (+)-3-Dimethylaminopyrrolidine to obtain the title compound.
- the EGFR D770_N771insNPG kinase expressed in the baculovirus expression system was purchased from Shanghai Univ Biological Inc.. Contains biotin-labeled peptide substrate TK Substrate-biotin, Eu-labeled specific phosphorylated peptide antibody TK Antibody-Cryptate, HTRF fluorescent receptor reagent Streptavidin-XL665 and 5 ⁇ kinase reaction buffer solution, detection buffer TK Kinase HTRF detection kit (#62TK0PEC) was purchased from Cisbio Bioassays (Codolet, France). Dithiothreitol (DTT), magnesium chloride, manganese chloride, adenosine triphosphate (ATP), dimethyl sulfoxide (DMSO) and HEPES buffer were obtained from Sigma at the highest level of purity available.
- DTT dithiothreitol
- magnesium chloride magnesium chloride
- manganese chloride adenosine triphosphate
- the phosphorylation reaction buffer is composed of 1M HEPES (pH 7.0), 5mM MgCl 2 , 1mM MnCl 2 , and 1mM DTT is added to the buffer immediately before the start of the experiment.
- the obtained gradient dilution solution is further diluted with a phosphorylation reaction buffer solution to obtain a working solution of the test compound dissolved in a reaction buffer solution containing 5% DMSO.
- the final concentrations of kinase, peptide substrate, ATP and DMSO The concentrations were 0.01ng/ul, 200nM, 4 ⁇ M and 1%.
- the reaction was performed at room temperature for 60 minutes in the dark.
- the final concentration of Streptavidin-XL665 in the WT EGFR kinase reaction system is 15.61 nM, and the final concentration of Streptavidin-XL665 in the EGFR D770_N771insNPG kinase reaction system is 31.25 nM.
- the antibody is diluted according to the final concentration provided by the supplier.
- Use Tecan( Switzerland) Multi-function microplate reader Spark reads the plate and detects two sets of homogeneous time-resolved fluorescence intensity.
- the excitation wavelength is 320nm and the emission wavelength is 665nm and 620nm, respectively.
- H358, HCC827, NCI-H1781, Calu-3 cells were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai), BaF3 EGFR WT, BaF3 EGFR D770_N771insSVD, BaF3 EGFR V769_D770insASV, BaF3 ERBB2A775_G776insYVMA cells were purchased from Beijing Kangyuan Bochuang, MDA-MB-231 , SK-BR-3, BT474 were purchased from Nanjing Kebai Biotechnology Co., Ltd.
- MEM medium MEM medium, RPMI1640 medium, penicillin-streptomycin double antibody, 0.5% trypsin (10X) and epidermal growth factor EGF were purchased from ThermoFisher (Waltham, MA, USA). Certified fetal bovine serum (FBS) was purchased from Biological Industries (Israel). Corning 96 and 384-well cell culture plates were purchased from CORNING (USA). Cell-Titer Purchased from Promega Corporation (Madison, WI, USA).
- the compound was diluted in DMSO to 12 points, 3-fold serial dilutions, starting from 2mM.
- 20 ⁇ L of the compound solution in the culture medium was added to each cell-plated well of the 384 plate according to a gradient. After adding the compound solution, the 384-well plate was placed in a 37°C, 5% CO 2 incubator and incubated for 3 days.
- Promega (Madison, WI, USA)'s CellTiter-Glo detection kit was used to determine cell viability by quantifying the ATP present in cell culture.
- Ref-1 was prepared according to the preparation method described in WO2015195228A1, and the structure is as follows:
- the selectivities are 5.5/5.0 and 1.3/3.3, respectively, which are 30/15 and 7.2/10 of Poziotininb and Ref-1, respectively. And 22/28, 5.2/18 times, indicating that the clinical treatment space is greatly improved and the drug effect is more obvious.
- Table 3 shows the inhibitory results of some compounds prepared according to the foregoing examples on the proliferation of HCC 827 and H358 WT cells.
- Table 4 shows the inhibitory results of some compounds prepared according to the foregoing examples on Calu-3, NCI-H1781 and BaF3 ERBB2A775_G776insYVMA cell proliferation.
- Example 2 inhibits the proliferation of BaF3 ERBB2 A775_G776insYVMA and NCI-H1781 cells is lower than that of Pyrotinib, which is currently in the clinical research stage of ERBB2, A775_G776insYVMA and ERBB2, G776_V777insV, which has high expression of non-small cell lung cancer, but it has high expression of Calu-3 on WT ERBB2.
- the proliferation inhibition of Pyrotinib is significantly lower than that of Pyrotinib, showing more excellent selectivity and clinical treatment space.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请提供一种式(I)化合物、其立体异构体或其药学上可接受的盐,以及其用于制备预防或治疗EGFR突变引起的相关疾病药物的用途。
Description
本申请属于化学医药领域,具体涉及一种EGFR酪氨酸激酶抑制剂及其用途。
肺癌是世界上最常见的恶性肿瘤之一,肺癌分为小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC),其中NSCLC包括鳞状细胞癌(鳞癌)、腺癌和大细胞癌。与SCLC相比,NSCLC的癌细胞生长分裂较慢,扩散转移相对较晚。NSCLC约占所有肺癌的80%,预后不良,约75%的患者发现的时候已处于中晚期。而表皮生长因子受体(EGFR)的过度表达和突变已被明确证实将导致不可控的细胞生长,与大部分癌症疾病的进程有关,尤其是NSCLC(Oncotarget.2016 Jul 5;7(27):41691-41702)。
EGFR是表皮生长因子受体(HER)家族成员之一,该家族由EGFR(Erb-Bl)、Erb-B2(HER-2/neu)、Erb-B3和Erb-B4组成。EGFR是一种糖蛋白,是表皮生长因子(EGF)细胞增殖和信号传导的受体,属于酪氨酸激酶型受体,细胞膜贯通,位于细胞膜表面(Clin Cancer Res;21(3)February 1,2015,526-533)。
在NSCLC病人中,EGFR不仅有过度表达,而且还在它的酪氨酸激酶结构区域有不依赖于配体结合的激酶活性异常激活突变。其中最常见的激酶活性突变是EGFR(Exon 19 del E746-A750)和EGFR(Exon 21 L858R),第一代已经上市的EGFR酪氨酸激酶抑制剂(EGFR-TKI)吉非替尼(gefitinib)和厄洛替尼(erlotinib)已经被批准用于治疗这两种突变,但第一代EGFR-TKI在治疗过程中产生耐药性,耐药性的产生与EGFR 790号位的苏氨酸置换为蛋氨酸(T790M)发生的二次突变相关。第二代的非可逆共价抑制剂,如阿法替尼(Afatinib)对治疗EGFR(delE746-A750)和EGFR(L858R)效果更好,但对耐药性T790M突变体效果不佳,其原因是对野生型EGFR比抑制EGFR(delE746-A750/T790M)和EGFR(L858R/T790M)耐药性突变体活性更高,从而表现出了剂量依赖性毒性(Biologics,2014,8:183-192),无法获得有效的治疗窗口。因此研究出第三代EGFR-TKI,比如AZD9291,CO-1686和HM61713。第三代EGFR-TKI是具有特异选择性的酪氨酸激酶抑制剂。相较于第一代和第二代EGFR-TKI,第三代的EGFR-TKI降低了对野生型的EGFR的抑制,减少临床上的毒副作用,可以使用更高的临床剂量获得较好的疗效。(J Clin Oncol 2014;32:abstr 8009;J Clin Oncol 2014;32:abstr 8010)。
另外一种异常激活进而诱导癌症发生的EGFR突变是外显子20插入突变(EGFR exon20 ins),先前的研究表明这类突变占所有的EGFR突变肺癌的4%-10%(PLoS ONE 2015 10(7):e0133859)。目前在临床上仍然没有药物能用于治疗(Mol Cancer Ther.2013,12,220),这类突变病人对现有上市的EGFR抑制剂药物都不敏感,目前标准治疗方案为细胞毒类化疗,预后效果差,副作用强,目前尚无靶向药物可用。靶向EGFR exon20插入突变的候选药物Poziotinib 和Ref-1已经进入临床研究,但它们对野生型EGFR抑制能力非常强,因此会带来较大的毒副作用,比如皮肤毒性等。严重限制了临床剂量的提高和临床药效。另外,还有最近刚刚进入临床的化合物CLN-081和DZ9008,虽然在体外活性上表明降低了对野生型的毒性,但它们的临床效果还没有进一步证实。综上,具有更高活性和低毒性的化合物仍有待开发。
发明内容
本申请公开了一类可作为EGFR蛋白激酶抑制剂的化合物以及其在制备预防或治疗EGFR相关疾病药物中的用途。
一方面,本申请提供式(I)化合物、其立体异构体或其药学上可接受的盐:
其中,Z
1为-NH-、-N(CH
3)-、-O-或-S-;
Z
2、Z
3、Z
4、Z
5各自独立地选自C或N;
环A选自芳基、杂芳基、部分不饱和的环烷基或部分不饱和的杂环烷基;
环B为杂环烷基或不存在;
每个R
2独立地选自氢、C
1-C
6烷基、卤代C
1-C
6烷基、卤素、羟基、硝基、氨基、氰基、羰基或烷氧基;
R
3选自氢、C
1-C
6烷基、卤代C
1-C
6烷基、卤素、羟基、硝基、氨基、氰基或烷氧基;
m、n分别独立地选自1、2或3。
在某些实施方案中,式(Ⅰ)是式(Ⅰa):
Z
1为-NH-、-N(CH
3)-、-O-或-S-;
Z
2、Z
3、Z
4、Z
5各自独立地选自C或N;
环A选自芳基、杂芳基、部分不饱和的环烷基或部分不饱和的杂环烷基;
环B为杂环烷基或不存在;
每个R
2独立地选自氢、C
1-C
6烷基、卤代C
1-C
6烷基、卤素、羟基、硝基、氨基、氰基、羰基或烷氧基;
m、n分别独立地选自1、2或3。
在某些实施方案中,Z
1为-NH-、-N(CH
3)-或-O-;
Z
2、Z
3、Z
4、Z
5各自独立地选自C或N,且Z
3和Z
4不同时为N;
每个R
2独立地选自氢、C
1-C
3烷基、卤代C
1-C
3烷基、卤素、氰基、羰基或烷氧基;并且
m、n分别独立地选自1或2。
在某些实施方案中,式(Ⅰ)选自如下化合物:
前述化合物可用于制备预防或治疗受体酪氨酸激酶突变,尤其是EGFR突变相关疾病药物;所述EGFR突变相关疾病为癌症,尤其是在EGFR的外显子20结构域中发生突变的相关癌症,如非小细胞肺癌,乳腺癌,脑癌,卵巢癌,胰腺癌,子宫癌,宫颈癌,皮肤癌,前列腺癌,膀胱癌,肝癌,胃肠组织癌,食道癌,甲状腺癌,白血病,淋巴瘤以及多发性骨髓瘤等。
另一方面,本申请还提供一种药物组合物,其包含治疗有效量的式(I)的化合物或其药学上可接受的盐、异构体;以及药学上可接受的载体或赋形剂。药学上可接受的载体或赋形 剂可包含任何常规药物载体或赋形剂。合适的药物载体包括惰性稀释剂或填充剂、水以及各种有机溶剂诸如水合物和溶剂。如果需要,药物组合物可含有另外的成分,诸如调味剂、粘合剂、赋形剂等。
前述药物组合物还可包含其它一种或多种抗癌药物,所述抗癌药物为小分子药物、单克隆抗体或融合蛋白药物。
本申请所提供的具有EGFR酪氨酸激酶抑制活性的化合物,对EGFR(D770_N771insNPG)插入突变激酶活性具有很强的抑制能力。对野生型EGFR高表达小鼠原B细胞(BaF3)增殖能力的抑制,大大低于目前处于临床研究阶段的Poziotinib和Ref-1,与此同时,能有效的抑制EGFR exon20插入突变高表达的BaF3细胞增殖。相比于单一的突变EGFR高表达肿瘤细胞增殖抑制活性,突变细胞相对于野生细胞抑制活性的选择性是作为临床治疗窗口更为重要和关键的指标。因此和目前临床化合物相比,本申请所提供的化合物在临床应用中能够使用更高的剂量而不带来明显的毒性,大大提高疗效,获得更好的预后效果。并且对常见的EGFR突变,EGFR(delE746-A750),Her2插入突变高表达肿瘤细胞的异常增殖都有良好的抑制效果。
术语:
除非有相反陈述,在说明书和权利要求书中使用的术语具有下述含义。
术语“异构体”包括给定结构的对映异构形式、非对映异构形式和几何(或构象)异构形式。例如,本申请包括每个不对称中心的R和S构型、Z和E双键异构体、Z和E构象异构体、单一立体化学异构体及对映异构体、非对映异构体和几何(或构象)异构体混合物。
术语“药学上可接受的盐”指,诸如其酸加成盐和/或碱盐。合适的酸加成盐由酸形成,其形成无毒盐,例如盐酸盐/氯化物。合适的碱盐由碱形成,其形成无毒盐,例如钙盐和钠盐。还可形成酸和碱的半盐,例如半硫酸盐和半钙盐。
术语“治疗有效量”是指本申请化合物的以下量,其(i)治疗具体的疾病、病症或障碍;(ii)减轻、缓解或消除具体的疾病、病症或障碍的一种或多种症状;或(iii)预防或延迟本申请所述具体的疾病、病症或障碍的一种或多种症状的发作。
术语“药学上可接受的载体或赋形剂”是指不破坏用其配制的化合物的药理活性的无毒载体、辅料或媒介物。
术语“烷基”指饱和脂肪族烃基团,其为包含1至20个碳原子的直链或支链基团,优选含有1至12个碳原子的烷基,更优选含有1至6个碳原子的烷基。含有1至6个碳原子的低级烷基的非限制性实施例包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、1,1-二甲基丙基、1,2-二甲基丙基、2,2-二甲基丙基、1-乙基丙基、2-甲基丁基、3-甲基丁基、正己基、1-乙基-2-甲基丙基、1,1,2-三甲基丙基、1,1-二甲基丁基、1,2-二甲基丁基、2,2-二甲基丁基、1,3-二甲基丁基、2-乙基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2,3-二甲基丁基等。
术语“烯基”指具有至少一个碳-碳双键的脂族烃,包括具有至少一个碳-碳双键的直链和支链。在一些实施方案中,烯基基团具有2至20个碳原子、2至10个碳原子、2至6个碳原子、3至6个碳原子或2至4个碳原子。例如,术语“C
2-6烯基”包括2至6个碳原子的直链或支链不饱和基团(具有至少一个碳-碳双键),包括但不限于乙烯基、1-丙烯基、2-丙烯基(烯丙基)、异丙烯基、2-甲基-1-丙烯基、1-丁烯基、2-丁烯基等。
术语“炔基”指具有至少一个碳-碳三键的脂族烃,包括具有至少一个碳-碳三键的直链和支链。在一些实施方案中,炔基基团具有2至20、2至10、2至6、或3至6个碳原子。例如,“C
2-6炔基”包括具有2至6个碳原子的如上定义的直链或支链烃链炔基基团。
术语“烷氧基”指-O-(烷基)和-O-(非取代的环烷基),其中烷基如上所定义。烷氧基的非限制性实例包括:甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基。
术语“环烷基”指饱和或部分不饱和单环或多环环状烃取代基,环烷基环包含3至20个碳原子,优选包含3至12个碳原子,更优选包含3至6个碳原子(例如3、4、5或6个碳原子),最优选包含5至6个碳原子。单环环烷基的非限制性实例包括环丙基、环丁基、环戊基、环戊烯基、环己基、环己烯基、环己二烯基、环庚基、环庚三烯基、环辛基等;多环环烷基包括螺环、稠环和桥环的环烷基。
术语“螺环烷基”指5至20元的单环之间共用一个碳原子(称螺原子)的多环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元(例如7、8、9或10元)。根据环与环之间共用螺原子的数目将螺环烷基分为单螺环烷基、双螺环烷基或多螺环烷基,优选为单螺环烷基和双螺环烷基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺环烷基。
术语“稠环烷基”指5至20元,系统中的每个环与体系中的其他环共享毗邻的一对碳原子的全碳多环基团,其中一个或多个环可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠环烷基,优选为双环或三环,更优选为5元/5元或5元/6元双环烷基。
术语“桥环烷基”指5至20元,任意两个环共用两个不直接连接的碳原子的全碳多环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥环烷基,优选为双环、三环或四环,更优选为双环或三环。
术语“杂环基”指饱和或部分不饱和单环或多环环状烃取代基,其包含3至20个环原子,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,但不包括-O-O-、-O-S-或-S-S-的环部分,其余环原子为碳。优选包含3至12个环原子,其中1~4个是杂原子;最优选包含3至8个环原子,其中1~3个是杂原子;最优选包含5至6个环原子,其中1~2或1~3个是杂原子。单环杂环基的非限制性实例包括吡咯烷基、咪唑烷基、四氢呋喃基、四氢吡喃基、四氢噻吩基、二氢咪唑基、二氢呋喃基、二氢吡唑基、二氢吡咯基、哌啶基、哌嗪基、 吗啉基、硫代吗啉基、高哌嗪基等,优选四氢吡喃基、哌啶基、吡咯烷基。多环杂环基包括螺杂环基、稠杂环基和桥杂环基。
术语“螺杂环基”指5至20元的单环之间共用一个原子(称螺原子)的多环杂环基团,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统。优选为6至14元,更优选为7至10元。根据环与环之间共用螺原子的数目将螺杂环基分为单螺杂环基、双螺杂环基或多螺杂环基,优选为单螺杂环基和双螺杂环基。更优选为4元/4元、4元/5元、4元/6元、5元/5元或5元/6元单螺杂环基。
术语“稠杂环基”指5至20元,系统中的每个环与体系中的其他环共享毗邻的一对原子的多环杂环基团,一个或多个环可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环稠杂环基,优选为双环或三环,更优选为5元/5元或5元/6元双环稠杂环基。
术语“桥杂环基”指5至14元,任意两个环共用两个不直接连接的原子的多环杂环基团,其可以含有一个或多个双键,但没有一个环具有完全共轭的π电子系统,其中一个或多个环原子为选自氮、氧或S(O)m(其中m是整数0至2)的杂原子,其余环原子为碳。优选为6至14元,更优选为7至10元。根据组成环的数目可以分为双环、三环、四环或多环桥杂环基,优选为双环、三环或四环,更优选为双环或三环。
所述杂环基包括如上所述的杂环基(包括单环、螺杂环、稠杂环和桥杂环)稠合于芳基、杂芳基或环烷基环上,其中与母体结构连接在一起的环为杂环基,其非限制性实例包括:
术语“芳基”指具有共轭的π电子体系的6至14元全碳单环或稠合多环(也就是共享毗邻碳原子对的环)基团,优选为6至10元,例如苯基和萘基。
术语“杂芳基”指包含1至4个杂原子、5至14个环原子的杂芳族体系,其中杂原子选自氧、硫和氮。杂芳基优选为5至10元,含1至3个杂原子;更优选为5元或6元,含1至2个杂原子;优选例如咪唑基、呋喃基、噻吩基、噻唑基、吡唑基、噁唑基、吡咯基、四唑基、吡啶基、嘧啶基、噻二唑、吡嗪基和哒嗪基等。
所述杂芳基包括如上所述的杂芳基稠合于芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为杂芳基环,其非限制性实例包括:
术语“羟烷基”指被羟基取代的烷基,其中烷基如上所定义。
术语“卤代烷基”指烷基被一个或多个卤素取代,其中烷基如上所定义。
术语“卤代烷氧基”指烷氧基被一个或多个卤素取代,其中烷氧基如上所定义。
术语“氘代烷基”指烷基被一个或多个氘原子取代,其中烷基如上所定义。
术语“氘代烷氧基”指烷氧基被一个或多个氘原子取代,其中烷氧基如上所定义。
术语“环烷基烷基”指烷基被一个或多个环烷基取代,其中环烷基和烷基如上所定义。
术语“环烷基氧基”指-O-环烷基,其中环烷基如上所定义。
术语“杂环基烷基”指烷基被一个或多个杂环基取代,其中杂环基和烷基如上所定义。
术语“芳基烷基”指烷基被一个或多个芳基取代,其中芳基和烷基如上所定义。
术语“羟基”指-OH基团。
术语“卤素”指氟、氯、溴或碘。
术语“氨基”指-NH
2。
术语“氰基”指-CN。
术语“硝基”指-NO
2。
术语“羧基”指-C(O)OH。
实施例1 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
步骤一:
将化合物1.1(15.000g,54.57mmol,1eq.)溶于DMSO(100mL)中,加入化合物1.2(6.67g,60.03mmol,1.1eq.),K
2CO
3(15.08g,109.14mmol,2eq.),加热至80℃,反应15小时。将体系倒入水(200mL)中,静置30min,过滤,滤饼烘干,得褐 色固体(7.350g,收率38.53%)。
步骤二:
将化合物1.3(2.500g,7.15mmol,1eq.)溶于二氧六环(100mL)中,加入化合物1.4(1.30g,8.58mmol,1.2eq.),Pd(dppf)Cl
2(523.35mg,715.25umol,0.1eq.),K
3PO
4(1.52g,7.15mmol,1eq.),H
2O(10mL),氮气置换三次,氮气保护,加热至60℃,反应1.5小时,将体系倒入水(150mL)中,EtOAC(300mL)萃取,分液,有机相用饱和NaCl水溶液洗一次,分液,有机相用无水硫酸镁干燥,过滤,浓缩,柱层析(正庚烷:EtOAC=15:1),得白色固体(2.100g,收率89.04%)。
步骤三:
将化合物1.5(2.100g,6.37mmol,1eq.)溶于二氧六环(100mL)中,加入化合物1.6(1.19g,6.37mmol,1eq.),Pd
2(dba)
3(583.16mg,636.84umol,0.1eq.),x-phos(607.18mg,1.27mmol,0.2eq.),Cs
2CO
3(4.15g,12.74mmol,2eq.),氮气置换三次,氮气保护,加热至100℃,反应4小时,体系冷却,过滤,滤液直接投下一步。
步骤四:
将上一步滤液,加入N,N,N'-三甲基乙二胺(3.25g,31.81mmol,5eq.),加热至8 0℃,反应15小时,将体系倒入水(120mL)中,用EtOAC(250mL)萃取,分液,有机相用饱和NaCl水溶液洗一次,分液,有机相用无水硫酸镁干燥,过滤,浓缩,柱层析(DCM:MeOH=30:1),得红色油状物(2.940g,收率:82.29%)。
步骤五:
将化合物1.8(2.940g,5.23mmol,1eq.)溶于EtOH(80mL)中,加入Fe(1.46g,26.17mmol,5eq.),NH
4Cl(1.29g,26.17mmol,5eq.),H
2O(20mL),加热至80℃,反应5小时。将体系过滤,用EtOAC(200mL)洗涤,滤液加入水(100mL),分液,有机相用饱和NaCl水溶液洗一次,分液,有机相用无水硫酸镁干燥,过滤,浓缩,得褐色固体(2.140g,收率:76.89%)。
步骤六:
将化合物1.9(2.140g,4.03mmol,1eq.)溶于DCM(20mL)中,干冰乙醇浴降至-20℃,加入三乙胺(814.66mg,8.05mmol,2eq.),化合物1.10(364.33mg,4.03mmol,1eq.),反应10min,向体系加入水(20mL),用DCM(100mL)萃取,分液,有机相用饱和NaCl水溶液洗一次,分液,有机相用无水硫酸镁干燥,过滤,浓缩,柱层析(DCM:MeOH=30:1),再用EtOAC打浆,得类白色固体(0.800g,33.93%)。
1H NMR(400MHz,DMSO-d6)(ppm):10.07(s,1H),8.53(s,1H),7.96-8.00(t,1H),7.90(m,2H),7.61(s,1H),7.41-7.44(d,2H),6.97-7.17(m,6H),6.36-6.43(dd,1H),6.17-6.22(dd,1H),5.72-5.75(dd,1H),3.79-3.81(d,6H),2.84-2.87(t,2H),2.70(s,3H),2.28-2.31(t,2H),2.20(s,6H)。LC-MS(m/z):587.00[M+H]
+。
实施例2 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-(对甲苯基氨基)嘧啶-2- 基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为对甲苯胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.13(s,1H),8.60(s,1H),7.96(s,1H),7.86(s,1H),7.84(s,1H),7.47-7.50(m,2H),7.42-7.45(d,2H),7.28-7.32(t,2H),6.94-6.98(m,3H),6.40-6.44(m,1H),6.18-6.22(dd,1H),5.73-5.76(dd,1H),3.80(s,3H),2.85-2.88(t,2H),2.71(s,3H),2.23-2.31(t,2H),2.18-2.22(m,9H)。LC-MS(m/z):569.69[M+H]
+。
实施例3 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-((2-甲基嘧啶-5-基)氨基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-甲基嘧啶-5-胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.08(brs,1H),8.84(s,2H),8.55(brs,1H),8.37(s,1H),8.12(s,1H),7.93(s,1H),7.50-7.54(m,2H),7.29-7.34(t,2H),6.97(s,1H),6.34(s,1H),6.14-6.18(d,1H),5.70-5.73(m,1H),3.79(s,3H),2.91-2.93(m,2H),2.71(s,3H),2.28-2.50(m,9H)。LC-MS(m/z):571.66[M+H]
+。
实施例4 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-((5-甲基吡嗪-2-基)氨基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为5-甲基吡嗪-2-胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.17(s,1H),9.24(s,1H),8.57(s,1H),8.41(s,1H),8.09(s,1H),8.03(s,1H),7.88(s,1H),7.51-7.54(m,2H),7.32-7.37(m,2H),7.02(s,1H),6.32-6.39(m,1H),6.13-6.17(dd,1H),5.70-5.72(dd,1H),3.80(s,3H),2.92(m,2H),2.74(m,3H),2.35(m,5H),2.24(m5H)。LC-MS(m/z):571.28[M+H]
+。
实施例5 N-(5-((5-(3-氯-4-氟苯基)-4-(对甲苯基氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为对甲苯胺,步骤二的化合物1.4替换为(3-氯-4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.10(s,1H),8.57(s,1H),8.11(s,1H),7.88(s,1H),7.86(s,1H),7.63-7.66(dd,1H),7.41-7.51(m,4H),6.94-7.0(m,3H),6.38-6.44(m,1H),6.18-6.23(dd,1H),5.73-5.74(d,1H),3.80(s,3H),2.88(m,2H),2.71(s,3H),2.31(m,2H),2.19-2.22(m,9H)。LC-MS(m/z):603.25[M+H]
+。
实施例6 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-(甲基(对甲苯基)氨基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为N,4-二甲基苯胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.07(s,1H),9.06(s,1H),7.86(s,1H),7.78(s,1H),7.01-7.03(m,3H),6.71-6.83(m,6H),6.35-6.41(dd,1H),6.18-6.23(dd,1H),5.70-5.73(dd,1H),3.89(s,3H),3.44(s,3H),2.87-2.88(m,2H),2.70(s,3H),2.20-2.30(m,8H),2.08(s,3H)。LC-MS(m/z):583.77[M+H]
+。
实施例7 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-(对甲苯氧基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为对甲酚,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.02(s,1H),8.41(s,1H),8.37(s,1H),8.16(s,1H),7.67-7.72(m,2H),7.10-7.15(m,4H),6.91(s,1H),6.39-6.43(dd,1H),6.22-6.27(dd,1H),5.75-5.78(dd,1H),3.76(s,3H),2.85(m,2H),2.67(s,3H),2.23-2.34(m,10H)。LC-MS(m/z):570.75[M+H]
+。
实施例8 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-(萘-1-基氧基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为萘-1-醇,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.0(brs,1H),8.45(s,1H),8.28(brs,1H),8.09(s,1H),7.96-7.98(m,1H),7.77-7.85(m,4H),7.43-7.57(m,4H),7.30-7.35(m,2H),6.83(s,1H),6.40(m,1H),6.22-6.26(d,1H),5.76-5.79(d,1H),3.66(s,3H),2.82(m,2H),2.64(s,3H),2.23-2.34(m,8H)。LC-MS(m/z):606.71[M+H]
+。
实施例9 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-((2-氟苯基)氨基)嘧啶-2- 基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.07(s,1H),8.50(s,1H),7.93(s,1H),7.78-7.88(m,3H),7.52-7.56(m,2H),7.31-7.36(t,2H),7.12-7.14(m,1H),6.95-7.05(m,3H),6.36-6.40(dd,1H),6.18-6.22(dd,1H),5.72-5.75(dd,1H),3.78(s,3H),2.83-2.86(t,3H),2.70(s,2H),2.27-2.30(t,2H),2.20(s,6H)。LC-MS(m/z):574.95[M+H]
+。
实施例10 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟-5-甲基苯基)氨基)-5-(4-氟苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-氟-5-甲基苯胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.92(brs,1H),8.45(brs,1H),8.11(s,1H),7.92(m,2H),7.50-7.58(m,3H),7.36-7.30(m,2H),7.0-7.04(m,1H),6.94(s,1H),6.85-6.86(m,1H),6.19-6.23(d,1H)5.73-5.76(d,1H),3.81(s,3H),2.93(m,2H),2.66(s,3H),2.18-2.37(m,9H)。LC-MS(m/z):589.04[M+H]
+。
实施例11 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟-4-甲基苯基)氨基)-5-(4-氟苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-氟-4-甲基苯胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.04(s,1H),8.57(s,1H),7.91(s,1H),7.78(s,1H),7.65-7.70(t,3H),7.51-7.55(m,2H),7.31-7.36(m,2H),6.96-6.99(m,2H),6.37-6.43(m,1H),6.18-6.23(dd,1H),5.73-5.76(dd,1H),3.79(s,3H),2.86(m,2H),2.70(s,3H),2.10-2.40(m,11H)。LC-MS(m/z):589.01[M+H]
+。
实施例12 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟-3-甲基苯基)氨基)-5-(4-氟苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-氟-3-甲基苯胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.04(s,1H),8.52(s,1H),7.94(s,2H),7.76-7.80(m,1H),7.60(s,1H),7.52-7.57(m,2H),7.32-7.36(m,2H),6.97(s,1H),6.85-6.90(m,2H),6.36-6.42(dd,1H),6.17-6.21(dd,1H),5.72-5.75(dd,1H),3.79(s,3H),2.85-2.88(t,2H),2.70(s,3H),2.17-2.40(m,11H)。LC-MS(m/z):588.50[M+H]
+。
实施例13 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(4-(三氟甲基)苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(4-(三氟甲基)苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.46(s,1H),8.10(s,1H),8.01(s,1H),7.89(s,1H),7.82-7.84(d,2H),7.73-7.75(d,2H),7.65-7.69(m,1H),7.00-7.16(m,3H),6.94(s,1H),6.36-6.43(dd,1H),6.18-6.23(dd,1H),5.73-5.76(dd,1H),3.78(s,3H),2.83-2.86(t,2H),2.69(s,3H),2.21-2.30(m,8H)。LC-MS(m/z):625.16[M+H]
+。
实施例14 N-(5-((5-(4-氰基苯基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(4-氰基苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.04(s,1H),8.46(s,1H),8.15(s,1H),8.02(s,1H),7.92-7.95(m,3H),7.73(d,2H),7.63-7.67(m,1H),7.0-7.16(m,3H),6.94(s,1H),6.37-6.43(dd,1H),6.19-6.23(dd,1H),5.73-5.76(dd,1H),3.78(s,3H),2.85(m,2H),2.68(s,3H),2.21-2.40(m,8H)。LC-MS(m/z):582.10[M+H]
+。
实施例15 N-(5-((5-(4,4-二氟环己-1-烯-1-基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(4,4-二氟环己-1-烯-1-基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.49(s,1H),7.94(s,2H),7.71-7.85(m,2H),7.16-7.21(m.3H),6.93(s,1H),6.35-6.42(m,1H),6.17-6.22(m,1H),5.72-5.75(dd,1H),3.78(s,3H),2.82-2.85(t,2H),2.68-2.71(m,5H),2.20-2.28(m,9H)。LC-MS(m/z):596.48[M+H]
+。
实施例16 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(4-丙基苯基)嘧 啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(4-丙基苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.51(s,1H),7.93-7.98(m,3H),7.66(s,1H),7.41-7.43(d,2H),7.33-7.35(d,2H),7.11-7.16(m,1H),6.97-7.02(m,3H),6.37-6.43(dd,1H),6.18-6.22(dd,1H),5.72-5.75(dd,1H),3.79(s,3H),2.87(m,2H),2.70(s,3H),2.60-2.64(t,2H),2.22-2.31(m,8H),1.62-1.67(m,2H),0.92-0.96(t,3H)。LC-MS(m/z):599.27[M+H]
+。
实施例17 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟-2-甲基苯基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(4-氟-2-甲基苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.52(s,1H),7.77(s,1H),7.72-7.75(m,2H),7.41(s,1H),7.29-7.32(m,1H),7.21-7.24(m,1H),7.0-7.17(m,4H),6.95(s,1H),6.36-6.43(dd,1H),6.18-6.22(dd,1H),5.73-5.76(dd,1H),3.80(s,3H),2.83-2.86(t,3H),2.69(s,3H),2.21-2.30(m,11H)。LC-MS(m/z):589.04[M+H]
+。
实施例18 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟-3-甲基苯基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(4-氟-3-甲基苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.52(s,1H),7.93(s,1H),7.86-7.93(m,2H),7.73(s,1H),7.41-7.43(m,1H)7.33-7.34(m,1H),7.24-7.28(t,1H),7.14(m,1H),7.0-7.04(m,2H),6.96(s,1H),6.36-6.38(m,1H),6.18-6.22(d,1H),5.72-5.75(d,1H)3.79(s,3H),2.84-2.87(t,2H),2.70(s,3H),2.28-2.30(m,5H),2.21(s,6H)。LC-MS(m/z):589.04[M+H]
+。
实施例19 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(吡啶-4-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为吡啶-4-基硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.03(s,1H),8.63-8.64(d,2H),8.45(s,1H),8.18(s,1H),8.06(s,1H),7.97(s,1H),7.67-7.70(t,1H),7.55-7.56(d,2H),7.01-7.17(m,3H),6.94(s,1H),6.37-6.43(dd,1H),6.19-6.23(d,1H),5.73-5.76(d,1H),3.78(s,3H),2.85(m,2H),2.69(s,3H),2.21-2.30(m,8H)。LC-MS(m/z):557.78[M+H]
+。
实施例20 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(2-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(2-甲氧基苯基)硼酸,得到标题 化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.06(s,1H),8.53(s,1H),8.05(m,1H),7.95(s,1H),7.90(s,1H),7.43-7.45(m,1H),7.30-7.32(m.2H),7.09-7.19(m,3H),6.96-6.99(m,3H),6.36-6.39(dd,1H),6.17-6.22(dd,1H),5.72-5.75(dd,1H),3.80-3.83(d,6H),2.85-2.88(m,2H),2.71(s,3H),2.29-2.31(m,2H),2.21(s,6H)。LC-MS(m/z):587.18[M+H]
+。
实施例21 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(3-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(3-甲氧基苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.06(s,1H),8.51(s,1H),7.96-8.0(m,3H),7.75(s,1H),7.41-7.45(m,1H),6.97-7.18(m,7H),6.46-6.43(dd,1H),6.17-6.22(dd,1H),5.72-5.75(dd,1H),3.80-3.85(d,6H),2.85-2,88(t,2H),2.70(s,3H),2.20-2.40(m,8H)。LC-MS(m/z):587.07[M+H]
+。
实施例22 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(1-甲基-1H-吡唑-5-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为1-甲基-1H-吡唑-5-硼酸频哪醇酯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.03(s,1H),8.44(s,1H),8.05(s,1H),7.99(s,1H),7.77-7.83(m,2H),7.56(s,1H),6.95-7.17(m,4H),6.43(s,1H),6.36-6.40(d,1H),6.18-6.23(dd,1H),5.73-5.76(dd,1H),3.75(s,3H),3.78(s,3H),2.84-2.87(t,2H),2.70(s,3H),2.28-2.30(t,2H),2.21(s,6H)。LC-MS(m/z):561.22[M+H]
+。
实施例23 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(呋喃-3-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为3-呋喃硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.02(s,1H),8.50(s,1H),8.27(s,1H),8.15(s,1H),7.86-8.03(m,3H),7.69(s,1H),7.15-7.20(m,1H),7.00-7.07(m,2H),6.96(s,1H),6.84(s,1H),6.39-6.45(m,1H),6.18-6.30(d,1H),5.73-5.76(d,1H),3.79(s,3H),2.89(m,2H),2.69(s,3H),2.24-2.50(m,8H)。LC-MS(m/z):547.04[M+H]
+。
实施例24 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(噻吩-3-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为3-噻吩硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.95(s,1H),8.41(s,1H),8.07(s,1H),7.94-7.98(m,2H),7.73-7.77(m,3H),7.35-7.37(dd,1H),7.14-7.20(m,1H),7.02-7.04(m,2H),6.95(s,1H),6.50(s,1H),6.21-6.25(d,1H),5.74-5.76(d,1H),3.81(s,3H),2.66-3.30(m,7H),2.10-2.50(m,6H)。LC-MS(m/z):563.08[M+H]
+。
实施例25 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(噻唑-5-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为5-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)噻唑,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.03(s,1H),9.21(s,1 H),8.43(s,1H),8.06-8.09(m,4H),7.72-7.76(m,1H),6.95-7.18(m,4H),6.36-6.43(m,1H),6.18-6.23(dd,1H),5.73-5.76(dd,1H),3.77(s,3H),2.84-2.87(t,2H),2.70(s,3H),2.29(t,2H),2.21(s,6H)。LC-MS(m/z):563.86[M+H]
+。
实施例26 N-(5-((5-(4-氰基环己-1-烯-1-基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为4-(4,4,5,5-四甲基-1,3,2-二氧杂戊硼烷-2-基)-3-环腈,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.02(s,1H),8.51(s,1H),7.78-7.81(m,3H),7.68(s,1H),7.16-7.19(m,1H),7.03-7.08(m,2H),6.93(s,1H),6.35-6.40(m,1H),6.18-6.22(dd,1H),5.81(m,1H),5.72-5.75(dd,1H),3.77(s,3H),3.15(m,2H),2.82-2.86(t,2H),2.68(s,3H),2.26-2.41(m,5H),2.20(s,6H),1.90-2.15(m,2H)。LC-MS(m/z):585.97[M+H]
+。
实施例27 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-氟苯基)-4-((3-氟苯基)氨基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为间氟苯胺,步骤二的化合物1.4替换为(4-氟苯基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.09(s,1H),9.69(s,1H),8.28-8.30(m,2H),8.11(s,1H),7.93(s,1H),7.47-7.54(m,3H),7.37-7.40(m,2H),7.28-7.33(m,1H),6.93(s,1H),6.68-6.72(m,1H),6.20-6.24(dd,1H),5.70-5.73(dd,1H),3.84(s,3H),3.28(m,5H),2.74(s,6H),2.59(s,3H)。LC-MS(m/z):575.02[M+H]
+。
实施例28 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((5-(4-乙氧基苯基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为4-乙氧基苯硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.07(s,1H),8.52(s,1H),7.99(m,1H),7.90-7.91(m,2H),7.59(m,2H),7.40-7.42(d,2H),7.12-7.15(m,1H),7.05-7.07(d,2H),6.92-7.02(m,3H),6.36-6.40(m,1H),6.17-6.22(dd,1H),5.72-5.75(dd,1H),4.06-4.11(m,2H),3.79(s,3H),2.86(t,2H),2.70(s,3H),2.29(m,1H),2.21(s,6H),1.34-1.38(t,3H)。LC-MS(m/z):601.24[M+H]
+。
实施例29 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(吡啶-3-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为吡啶-3-硼酸,得到标题化合物。1H NMR(400MHz,DMSO-d6)(ppm):10.04(s,1H),8.69(s,1H),8.57-8.59(d,1H),8.46(s,1H),8.10(s,1H),7.85-7.98(m,2H),7.65-7.69(t,1H),7.48-7.51(m,1H),7.00-7.16(m,3H),6.94(s,1H),6.37-6.44(m,1H),6.19-6.23(d,1H),5.73-5.76(d,1H),3.79(s,3H),2.86(m,2H),2.68(s,3H),2.22-2.30(m,9H).LC-MS(m/z):558.00[M+H]
+。
实施例30 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((5-(4-甲氧基苯基)-4-((2-甲氧基苯基)氨基)嘧啶-2-基)氨基)苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为邻甲氧基苯胺,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.08(s,1H),8.57(s,1H),8.37-8.39(d,1H),8.10(s,1H),7.91(s,1H),7.69(s,1H),7.41-7.43(d,2H),7.11-7.13(m,2H),6.86-7.01(m,3H),6.73-6.76(t,1H),6.37-6.44(m,1H),6.16-6.20(d,1H),5.71-5.74(d,1H),3.83(s,3H),3.80(s,3H),3.71(s,3H),2.90(m,2H),2.73(s,3H),2.22-2.30(m,8H).LC-MS(m/z):598.70[M+H]
+。
实施例31 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟-3-甲基苯基)氨基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-氟-3-甲基苯胺,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.06(s,1H),8.55(s,1H),7.92-7.96(m,3H),8.10(s,1H),7.42-7.46(m,3H),6.86-7.09(m,6H),6.38(s,1H),6.20(s,1H),5.73(s,1H),3.83(s,3H),3.80(s,3H),3.71(s,3H),2.90(m,2H),2.73(s,3H),2.22-2.30(m,8H).LC-MS(m/z):600.59[M+H]
+。
实施例32 N-(5-((5-(4,4-二氟环己-1-烯-1-基)-4-((2-氟-3-甲基苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-氟-3-甲基苯胺,步骤二的化合物1.4替换为4,4-二氟环己-1-烯基硼酸频那醇酯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.02(s,1H),8.49(s,1H),7.84(s,1H),7.69-7.84(m,3H),6.88-6.94(m,3H),6.39-6.44(m,1H)6.17-6.21(d,1H),5.72-5.74(m,2H)3.77(s,3H),2.86(s,2H),2.71-2.75(m,2H)2.68(s,3H),2.48(s,3H),2.21-2.31(m,12H).LC-MS(m/z):610.68[M+H]
+。
实施例33 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(咪唑并[1,2-a]吡啶-7-酰基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为咪唑并[1,2,A]吡啶-7-硼酸酯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.61-8.63(dd,1H),8.49(s,1H),8.13(s,1H),8.07(s,1H),8.00(s,1H),7.86(s,1H),7.06(t,1H),7.622(s,1H),7.619(s,1H)6.95-7.15(m,5H),6.36-6.40(m,1H),6.19-6.23(d,1H),5.73-5.76(d,1H),3.79(s,3H),2.84-2.86(t,2H),2.69(s,3H),2.29(t,2H),2,21(s,6H).LC-MS(m/z):596.87[M+H]
+。
实施例34 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(6-甲氧基吡啶-3-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换2-甲氧基-5-吡啶硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.0(s,1H),8.45(s,1H),8.25(d,1H),7.92-7.95(m,2H),7.77-7.82(m,2H),7.68-7.69(m,1H),7.02-7.17(m,3H),6.92-7.94(m,2H),6.50(m,1H),6.19-6.24(dd,1H),5.73-5.76(dd,1H),3.92(s,3H),3.80(s,3H),2.92(t,2H),2.67(s,3H),2.40-2.50(m,2H),2.30(s,6H).LC-MS(m/z):588.11[M+H]
+。
实施例35 N-(5-((5-(4,4-二氟环己-1-烯-1-基)-4-((2-氟-5-甲基苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-氟-5-甲基苯胺,步骤二的化合物1.4替换为4,4-二氟环己-1-烯基硼酸频那醇酯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.96(s,1H),8.49(s,1H),7.81-7.84(m,2H),7.64(s,1H),7.51-7.53(m,1H),7.02-7.07(m,1H),6.88-6.92(m,2H),6.35-6.42(m,1H),6.17-6.21(d,1H),5.71-5.74(m,2H),3.78(s,3H),2.85(s,2H),2.70-2.74(m,2H)2.66(s,3H),2.48(s,3H),2.21-2.31(m,12H).LC-MS(m/z):610.68[M+H]
+。
实施例36 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(咪唑并[1,2-a]吡啶-6-酰基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为咪唑并[1,2-A]吡啶-6-硼酸,得到标题化合物。1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.66(t,1H),8.51(s,1H),8.15(s,1H),8.01(s,1H),7.97(s,1H),7.78(s,1H),7.62-7.66(m,3H),7.28-7.31(dd,1H),7.01-7.14(m,3H),6.94(s,1H),6.36-6.40(m,1H),6.19-6.23(dd,1H),5.73-5.76(dd,1H),3.79(s,3H),2.84(t,2H),2.69(s,3H),2.28(t,2H),2.21(s,6H)。LC-MS(m/z):596.48[M+H]
+。
实施例37 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(1-甲基-2-氧代-1,2-二氢吡啶-4-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为(1-甲基-2-氧-1,2-二氢吡啶-4-基)硼酸,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.98(s,1H),8.35(s,1H),8.16(s,1H),8.02(s,1H),7.95(s,1H),7.76-7.78(m,1H),7.66-7.68(m,1H),6.92-7.18(m,4H),6.36-6.50(m,3H),6.20-6.24(d.1H),5.74-5.77(d,1H),3.78(s,3H),3.45(s,3H),2.90(s,2H),2.66(s,3H),2.26-2.50(m,8H)。LC-MS(m/z):587.65[M+H]
+。
实施例38 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(4-甲氧基环己-1 -烯-1-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为4-甲氧基环己烯-1-硼酸频哪醇酯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.05(s,1H),8.51(s,1H),7.91-7.96(m,1H),7.82(s,1H),7.71-7.73(m,2H),7.16-7.21(m,1H),7.01-7.06(m,2H),6.94(s,1H),6.35-6.38(m,1H),6.17-6.22(dd,1H),5.72-5.75(dd,1H),3.79(s,3H),3.55(t,1H),3.33(s,3H),2.85(t,2H),2.70(s,3H),2.46(m,2H),2.13-2.30(m,11H),2.00(m,1H),1.75(m,1H)。LC-MS(m/z):591.22[M+H]
+。
实施例39 N-(5-((4-((3-氯-2-氟苯基)氨基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-氟-3-氯苯胺,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.12(s,1H),9.73(s,1H),8.24(s,1H),7.82-7.94(m,3H),7.41-7.43(m,2H)7.17-7.21(m,1H),6.89-7.08(m,5H),6.20-6.24(d,1H),5.71-5.74(d,1H),3.84(s,3H),3.81(s,3H),3.26(s,4H),2.72(s,6H),2.57(s,3H).LC-MS(m/z):621.11[M+H]
+。
实施例40 (R)-N-(2-(3-(二甲基氨基)吡咯烷-1-基)-5-((4-((2-氟苯基)氨基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤四的N,N,N'-三甲基乙二胺替换为(3R)-(+)-3-二甲氨基吡咯烷,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.27(s,1H),7.94(t,1H),7.89(s,1H),7.71(s,1H),7.63-7.65(dd,2H),7.39-7.42(dd,2H),7.14-7.17(m,1H),7.03-7.09(m,4H),6.47-6.54(m,2H),6.15-6.19(dd,1H),5.67-5.70(dd,1H),3.82(s,3H),3.81(s,3H),3.15-3.19(m,3H),2.66(m,1H),2.16(s,6H),2.07(m,1H),1.70(m,1H)LC-MS(m/z):599.09[M+H]
+。
实施例41 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-(吲哚-1-基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为吲哚啉,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.09(s,1H),8.68(s,1H),8.09(s,1H),7.95(s,1H),7.30-7.32(m,2H),7.22-7.24(d,1H),7.08-7.10(d,1H),6.98(s,1H),6.92-6.94(d,2H),6.82-6.85(m,1H),6.71-6.74(m,1H),6.38-6.44(m,1H),6.20-6.25(dd,1H),5.73-5.76(dd,1H),3.82(s,3H),3.81(s,3H),3.54-3.58(t,2H),2.88-2.92(m,4H),2.70(s,3H),2.22-2.30(m,8H).LC-MS(m/z):595.04[M+H]
+。
实施例42 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丁-2-炔酰胺
使用实施例1相似的方法,将步骤六的化合物丙烯酰氯替换为2-丁炔酰氯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.75(s,1H),8.85(s,1H),8.17(s,1H),7.93(s,1H),7.77-7.85(m,3H),7.42-7.44(m,2H),7.07-7.14(m,4H),6.86(m,1H),3.86(s,3H),3.82(s,3H),3.22-3.28(m,4H),2.79(s,6H),2.61(s,3H),2.11(s,3H).LC-MS(m/z):599.31[M+H]
+。
实施例43 N-(2-((2-(二甲氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)-2-氟丙烯酰胺
使用实施例1相似的方法,将步骤六的化合物丙烯酰氯替换为2-氟丙烯酰氯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.86(s,1H),8.84(s,1H),8.12(s,1H),7.94(s,1H),7.92(m,1H),7.75(m,2H),7.42-7.44(d,1H),7.21(m,2H),7.07-7.19(m,2H),6.95(s,1H),5.72-5.84(d,1H),5.48-5.53(dd,1H),3.89(s,3H),3.82(s,3H),3.28(m,2H),3.08(m,3H),2.74(s,6H),2.60(s,3H)LC-MS(m/z):605.24[M+H]
+。
实施例44 (R)-N-(5-((5-(4,4-二氟环己基-1-烯-1-基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-2-(3-(二甲氨基)吡咯烷-1-基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,步骤二的化合物1.4替换为4,4-二氟环己-1-烯基硼酸频那醇酯,将步骤四的N,N,N'-三甲基乙二胺替换为(3R)-(+)-3-二甲氨基吡咯烷,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.22(s,1H),7.87(s,1H),7.81(s,1H),7.73-7.74(m,1H),7.62(s,1H),7.54(s,1H),7.17-7.20(m,1H),7.09-7.7.12(m,2H),6.46-6.54(m,2H),6.16-6.19(m,1H),5.68-5.71(m,1H),3.80(s,3H),3.30-3.31(m,2H),3.13-3.17(m,3H),2.67-2.75(m,3H),2.49(m,4H),2.06-2.23(m,8H).LC-MS(m/z):609.25[M+H]
+。
实施例45 N-(5-((5-(4,4-二氟环己-1-烯-1-基)-4-((2-氟苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)-2-氟丙烯酰胺
使用实施例1相似的方法,步骤二的化合物1.4替换为4,4-二氟环己-1-烯基硼酸频那醇酯,将将步骤六的化合物丙烯酰氯替换为2-氟丙烯酰氯,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.61(s,1H),8.41(s,1H),7.95(s,1H),7.85(s,1H),7.67-7.82(m,3H),7.01-7.18(m,4H),5.74(m,1H),5.54-5.68(dd,1H),5.27-5.42(dd,1H),3.80(s,3H),2.89-2.92(t,2H),2.64-2.72(m,5H),2.52(m,1H),2.10-2.22(m,10H).LC-MS(m/z):615.22[M+H]
+。
实施例46 (R)-N-(2-(3-(二甲基氨基)吡咯烷-1-基)-5-((4-((2-氟苯基)氨基)-5-(6-甲氧基吡啶-3-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤二的化合物1.4替换为2-甲氧基-5-吡啶硼酸,将步骤四的N,N,N'-三甲基乙二胺替换为(3R)-(+)-3-二甲氨基吡咯烷,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):9.22(s,1H),8.23-8.24(d,1H),7.96(s,1H),7.89(s,1H),7.80-7.81(dd,1H),7.60-7.79(m,3H),7.07-7.18(m,3H),6.91-6.93(d,1H),6.47-6.54(m,2H),6.15-6.20(m,1H),5.68-5.71(dd,1H),3.90(s,3H),3.81(s,3H),3.35-3.65(m,1H),3.12-3.30(m,3H),2.60-2.72(m,1H),2.05-2.30(m,7H),1.72-1.82(m,1H).LC-MS(m/z):599.67[M+H]
+
实施例47 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-(二甲基磷酰基)苯基)氨基)-5-(4-甲氧基苯基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,将步骤一的化合物1.2替换为2-(二甲基氧磷基)苯胺,得到标题化合物。
1H NMR(400MHz,DMSO-d6)(ppm):10.21(s,1H),10.08(s,1H),8.52(s,1H),8.30-8.33(m,1H),7.94(s,1H),7.90(s,1H),7.29-7.42(m,4H),6.96-6.98(m,4H),6.43(s,1H),6.20-6.24(d,1H),5.75-5.77(d,1H),3.82(s,3H),2.91(m,5H),2.69(s,3H),2.26-2.34(m,8H),1.60-1.64(d,6H)LC-MS(m/z):644.58[M+H]
+。
实施例48 N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-5-((4-((2-氟苯基)氨基)-5-(1-甲基-6-氧代-1,6-二氢吡啶-3-基)嘧啶-2-基)氨基)-4-甲氧基苯基)丙烯酰胺
使用实施例1相似的方法,步骤二的化合物1.4替换为(1-甲基-6-氧代-1,6-二氢吡啶-3-基)硼酸,得到标题化合物。
1HNMR(400MHz,DMSO-d6)(ppm):9.98(s,1H),8.35(s,1H),8.16(s,1H),8.02(s,1H),7.95(s,1H),7.76-7.78(d,1H),7.66-7.70(t,1H),6.92-7.18(m,4H),6.36-6.50(m,3H),6.20-6.24(d,1H),5.74-5.77(d,1H),3.78(s,3H),3.45(s,3H),2.90(s,2H),2.66(s,3H),2.26-2.50(m,8H)。LC-MS(m/z):587.65[M+H]
+。
实验例1 EGFR D770_N771insNPG激酶活性抑制测定
在杆状病毒表达系统中表达的EGFR D770_N771insNPG激酶购自上海优宁维(univ Biological Inc.)。含有生物素标记的多肽底物TK Substrate-biotin、Eu标记的特异性磷酸化多肽抗体TK Antibody-Cryptate,HTRF荧光受体试剂Streptavidin-XL665和5×激酶反应缓冲溶液、检测缓冲液Detection buffer的TK激酶HTRF检测试剂盒(#62TK0PEC)购自Cisbio Bioassays(Codolet,France)。二硫苏糖醇(DTT)、氯化镁、氯化锰、三磷酸腺苷(ATP)、二甲基亚砜(DMSO)和HEPES缓冲液以可获得的最高纯度水平从Sigma获得。
EGFR激酶活性抑制测定的一般方法:磷酸化反应缓冲液由1M HEPES(pH 7.0)、5mM MgCl
2、1mM MnCl
2组成,实验开始前在该缓冲液中即时加入1mM DTT。配置待测化合物DMSO存储母液,并根据实验所需,采用DMSO进行三倍浓度梯度稀释。所得梯度稀释溶液进一步采用磷酸化反应缓冲溶液进行稀释,获得待测化合物溶于含有5%DMSO的反应缓冲液的工作溶液。将2μL化合物工作溶液溶液和稀释于反应缓冲液的4μL EGFR激酶溶液添加到白色低体积384孔微量滴定板中,再加入溶于反应缓冲液中的4μL ATP和生物素标记的多肽底物的混合溶液,开始磷酸化反应。在WT EGFR实验中,WT激酶、多肽底物、ATP和DMSO的最终浓度分别为0.01ng/ul、500nM、4μM和1%,在EGFR D770_N771insNPG实验中,激酶、多肽底物、ATP和DMSO的最终浓度分别为0.01ng/ul、200nM、4μM和1%。避光条件下反应在室温下执行60分钟。分别加入稀释于检测缓冲液中的TK Antibody-Cryptate抗体和Streptavidin-XL665各5μL,室温孵育60分钟。WT EGFR激酶反应体系中Streptavidin-XL665终浓度为15.61nM,EGFR D770_N771insNPG激酶反应体系中Streptavidin-XL665终浓度为31.25nM,抗体按照供应商提供的最终浓度稀释。使用Tecan(
Switzerland)多功能酶标仪Spark进行读板,检测两组均相时间分辨荧光强度,其中激发波长为320nm,发射波长分别为665nm和620nm。使用Prism 7(La Jolla,15 CA)对665nm/620nm荧光强度比值相对于抑制剂浓度进行做图,采用S形剂量依赖曲线模型对所得抑制曲线记性你和,获得抑制剂的IC
50值。根据前述实施例制备的部分化合物的EGFR D770_N771insNPG激酶抑制活性IC
50测定结果见表1。
表1
化合物 | IC 50(nM) |
实施例1 | 0.85 |
实施例2 | 0.83 |
实施例9 | 2.00 |
实施例10 | 5.67 |
实施例11 | 4.93 |
实施例12 | 8.94 |
实验结果显示本申请所述化合物能有效的抑制EGFR D770_N771insNPG激酶活性,其中实施例1,2的IC
50均小于1nM。
实验例2细胞增殖抑制实验
H358、HCC827、NCI-H1781、Calu-3细胞购自中国科学院细胞库(上海),BaF3 EGFR WT、BaF3 EGFR D770_N771insSVD、BaF3 EGFR V769_D770insASV、BaF3 ERBB2A775_G776insYVMA细胞购自北京康源博创,MDA-MB-231、SK-BR-3、BT474购自南京科佰生物科技有限公司。MEM培养基、RPMI1640培养基、青霉素-链霉素双抗、0.5%的胰酶(10X) 和表皮细胞生长因子EGF购自ThermoFisher(Waltham,MA,USA)。经认证的胎牛血清(FBS)购自Biological Industries(Israel)。康宁96和384孔细胞培养板购自CORNING(USA)。Cell-Titer
购自Promega Corporation(Madison,WI,USA)。
为了评估合成化合物对肺癌细胞H358、HCC827、NCI-H1781、Calu-3和BaF3 EGFR WT、BaF3 EGFR D770_N771insSVD、BaF3 EGFR V769_D770insASV、BaF3 ERBB2 A775_G776insYVMA细胞增殖的抑制能力,将Calu-3指数增长的细胞接种于含10%牛血清和1%青霉素-链霉素双抗的MEM培养基,H358、HCC827、NCI-H1781、BaF3 EGFR D770_N771insSVD、BaF3 EGFR V769_D770insASV、BaF3 ERBB2 A775_G776insYVMA指数增长的细胞接种于含10%牛血清和1%青霉素-链霉素双抗的RPMI1640培养基,BaF3 EGFR WT指数增长的细胞接种于含10%牛血清、1%青霉素-链霉素双抗和50ng/mL EGF的RPMI1640培养基,HCC827、NCI-H1781、Calu-3、BaF3 ERBB2 A775_G776insYVMA密度为75000个细胞/mL,H358密度为100000个细胞/mL,BaF3 EGFR D770_N771insSVD、BaF3 V769_D770insASV密度为50000个细胞/mL,BaF3 EGFR WT密度为125000个细胞/mL,384孔板,每孔20μL,并放置在37℃,5%CO
2的培养箱中过夜。将化合物在DMSO中稀释至12个点、3倍梯度稀释液,从2mM开始。将化合物储备板的1μL DMSO溶液添加到99μL细胞培养基(测定中化合物的最终最高浓度为10μM,并且DMSO的最终浓度为0.5%)。将培养基中的20μL化合物溶液按照梯度加到384板的每个铺细胞的孔中。在加入化合物溶液后,将384孔板放置于37℃,5%CO
2培养箱中孵育3天。采用Promega(Madison,WI,USA)的CellTiter-Glo检测试剂盒,通过定量细胞培养中存在的ATP,测定细胞活力。20分钟的孵育后使用TECAN公司的SPARK多功能酶标仪在化学发光的程序下进行读数。在Prism 7(LaJolla,CA)中使用S形剂量反应模型(可变斜率,四个参数)确定化合物使细胞成活率抑制50%的浓度(IC
50值)。
实验中所使用的药性对照物Poziotinib、Osimertinib、Pyrotinib均以市售方式获得,Ref-1根据WO2015195228A1记载的制备方法制得,结构如下:
根据前述实施例制备的部分化合物对于BaF3 EGFR WT、BaF3 EGFR D770_N771insSVD、BaF3 EGFR V769_D770insASV细胞增殖抑制的结果见表2。
表2
结果显示,本申请化合物对WT EGFR高表达BaF3细胞增殖抑制的活性均远低于目前两个处于临床研究阶段的候选药物,预示着由此带来的毒性将大大降低。对于WT EGFR和EGFR Exon20插入中最为广泛的两种突变D770_N771insSVD和V769_D770insASV高表达的BaF3细胞增殖抑制活性之间相比较所得的选择性,目前两个临床化合物分别为0.18/0.33和0.25/0.18,表明临床疗效剂量远高于毒性剂量,因而临床应用会受到极大限制。而本申请大部分化合物的选择性明显高于临床化合物,比如其中实施例9和13,选择性分别为5.5/5.0和1.3/3.3,分别是Poziotininb和Ref-1的30/15,7.2/10和22/28,5.2/18倍,预示着临床治疗空间大大提高和药效更为明显。
根据前述实施例制备的部分化合物对于HCC 827、H358 WT细胞增殖抑制的结果见表3。
表3
结果显示本申请化合物对表达野生型EGFR的H358 NSCLC细胞增殖抑制要远低于Poziotinib,接近甚至低于临床安全性得到完全验证的第三代EGFR抑制剂Osimertinib。
根据前述实施例制备的部分化合物对于Calu-3、NCI-H1781及BaF3 ERBB2A775_G776insYVMA细胞增殖抑制的结果见表4。
表4
结果显示虽然实施例2对BaF3 ERBB2 A775_G776insYVMA和NCI-H1781细胞增殖的抑制要低于目前处于ERBB2 A775_G776insYVMA和ERBB2 G776_V777insV高表达非小细胞肺癌治疗临床研究阶段的Pyrotinib,但对WT ERBB2高表达Calu-3的增殖抑制要明显低于Pyrotinib,显示出更为优异的选择性和临床治疗空间。
根据前述实施例制备的部分化合物对于BaF3 EGFR D770_N771insSVD、BaF3 EGFR V769_D770insASV、H358 WT细胞增殖抑制的结果见表5。
表5
Claims (13)
- 式(I)化合物、其立体异构体或其药学上可接受的盐:其中,Z 1为-NH-、-N(CH 3)-、-O-或-S-;Z 2、Z 3、Z 4、Z 5各自独立地选自C或N;环A选自芳基、杂芳基、部分不饱和的环烷基或部分不饱和的杂环烷基;环B为杂环烷基或不存在;每个R 2独立地选自氢、C 1-C 6烷基、卤代C 1-C 6烷基、卤素、羟基、硝基、氨基、氰基、羰基或烷氧基;R 3选自氢、C 1-C 6烷基、卤代C 1-C 6烷基、卤素、羟基、硝基、氨基、氰基或烷氧基;m、n分别独立地选自1、2或3。
- 根据权利要求1所述的化合物、其立体异构体或其药学上可接受的盐,其中式(Ⅰ)是式(Ⅰa):Z 1为-NH-、-N(CH 3)-、-O-或-S-;Z 2、Z 3、Z 4、Z 5各自独立地选自C或N;环A选自芳基、杂芳基、部分不饱和的环烷基或部分不饱和的杂环烷基;环B为杂环烷基或不存在;每个R 2独立地选自氢、C 1-C 6烷基、卤代C 1-C 6烷基、卤素、羟基、硝基、氨基、氰基、羰基或烷氧基;m、n分别独立地选自1、2或3。
- 权利要求1-6任一项所述的化合物用于制备预防或治疗受体酪氨酸激酶突变引起的相关疾病药物的用途。
- 根据权利要求7所述的用途,其中所述受体酪氨酸激酶突变为EGFR突变。
- 根据权利要求8所述的用途,其中所述EGFR突变引起的相关疾病为癌症。
- 根据权利要求9所述的用途,其中所述癌症为非小细胞肺癌,乳腺癌,脑癌,卵巢癌,胰腺癌,子宫癌,宫颈癌,皮肤癌,前列腺癌,膀胱癌,肝癌,胃肠组织癌,食道癌,甲状腺癌,白血病,淋巴瘤或多发性骨髓瘤。
- 根据权利要求8所述的用途,其中所述EGFR突变引起的相关疾病为在EGFR的外显子20结构域中发生突变引起的相关癌症。
- 一种药物组合物,其包含治疗有效量的权利要求1-6任一项所述的化合物以及药学上可接受的载体或赋形剂。
- 根据权利要求12所述的药物组合物,其还包含其它一种或多种抗癌药物,所述抗癌药物为小分子药物、单克隆抗体或融合蛋白药物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010193366.0A CN113493420A (zh) | 2020-03-18 | 2020-03-18 | Egfr酪氨酸激酶抑制剂及其用途 |
CN202010193366.0 | 2020-03-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021185298A1 true WO2021185298A1 (zh) | 2021-09-23 |
Family
ID=77770156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/081405 WO2021185298A1 (zh) | 2020-03-18 | 2021-03-18 | Egfr酪氨酸激酶抑制剂及其用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113493420A (zh) |
WO (1) | WO2021185298A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094355A1 (en) * | 2020-10-30 | 2022-05-05 | Lengo Therapeutics, Inc. | Pyrimidine compounds, compositions, and medicinal applications thereof |
WO2023215431A1 (en) * | 2022-05-04 | 2023-11-09 | Blueprint Medicines Corporation | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016054987A1 (zh) * | 2014-10-11 | 2016-04-14 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
CN105601573A (zh) * | 2014-11-24 | 2016-05-25 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
WO2019177375A1 (ko) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
-
2020
- 2020-03-18 CN CN202010193366.0A patent/CN113493420A/zh active Pending
-
2021
- 2021-03-18 WO PCT/CN2021/081405 patent/WO2021185298A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016054987A1 (zh) * | 2014-10-11 | 2016-04-14 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
CN105601573A (zh) * | 2014-11-24 | 2016-05-25 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
CN108017633A (zh) * | 2018-01-30 | 2018-05-11 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-2-氟代丙烯酰胺衍生物及应用 |
WO2019177375A1 (ko) * | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Non-Patent Citations (2)
Title |
---|
DATABASE REGISTRY 1 October 2019 (2019-10-01), ANONYMOUS: "2-Propenamide, N-[5-[[5-(3, 6-dihydro-2H-pyran-4-yl)-4-[(2, 4-dimethoxyphenyl)amino]-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-", XP055851369, retrieved from STN Database accession no. 2376210-32-9 * |
DATABASE REGISTRY 1 October 2019 (2019-10-01), ANONYMOUS: "2-Propenamide, N-[5-[[5-(3, 6-dihydro-2H-pyran-4-yl)-4-[[2-(dimethylphosphinyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxyphenyl]-", XP055851372, retrieved from STN Database accession no. 2376210-26-1 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022094355A1 (en) * | 2020-10-30 | 2022-05-05 | Lengo Therapeutics, Inc. | Pyrimidine compounds, compositions, and medicinal applications thereof |
WO2023215431A1 (en) * | 2022-05-04 | 2023-11-09 | Blueprint Medicines Corporation | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
Also Published As
Publication number | Publication date |
---|---|
CN113493420A (zh) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111635408B (zh) | 三唑并-嘧啶化合物和其用途 | |
AU2013300344B2 (en) | N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer | |
WO2018045957A1 (zh) | 一种cdk4/6抑制剂及其制备方法和应用 | |
US7998977B2 (en) | Inhibitors of AKT (protein kinase B) | |
US20220227729A1 (en) | Identification and use of kras inhibitors | |
KR20180048635A (ko) | Kit 및 pdgfr에 관련된 장애를 치료하는데 유용한 조성물 | |
EA021306B1 (ru) | Ингибитор stat3, содержащий хинолинкарбоксамидное производное в качестве активного ингредиента | |
WO2017114383A1 (zh) | 一类新型的egfr野生型和突变型的激酶抑制剂 | |
EA034866B1 (ru) | Замещенные пиримидиновые ингибиторы bmi-1 | |
WO2016011979A1 (zh) | 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途 | |
US20070293484A1 (en) | Thiophene Heteroaryl Amines | |
AU2007245496A1 (en) | Amino-ethyl-amino-aryl (AEAA) compounds and their use | |
WO2014079232A1 (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
WO2015188747A1 (zh) | 作为egfr抑制剂的苯基取代的三嗪类化合物及其应用 | |
WO2021185298A1 (zh) | Egfr酪氨酸激酶抑制剂及其用途 | |
US20240025916A1 (en) | Kras g12c inhibitors | |
KR20120103553A (ko) | 신규 1,2,3,4-테트라히드로-피리미도(1,2-a)피리미딘-6-온 유도체, 그의 제조법 및 그의 제약 용도 | |
WO2023279938A1 (zh) | 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用 | |
WO2017143874A1 (zh) | 一种取代的恶二唑类化合物及包含该化合物的组合物及其用途 | |
CN105884695A (zh) | 杂环衍生物类酪氨酸激酶抑制剂 | |
WO2021063335A1 (zh) | Erk1/2蛋白激酶抑制剂及其用途 | |
ES2792989T3 (es) | Compuesto de piridinona y utilización del mismo | |
WO2020224607A1 (zh) | Ezh2抑制剂及其用途 | |
WO2021185297A1 (zh) | Egfr酪氨酸激酶抑制剂及其用途 | |
CN114206867A (zh) | 用于对抗癌症的作为bmx抑制剂的苯并[h][1,6]萘啶-2(1h)-酮 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21770553 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21770553 Country of ref document: EP Kind code of ref document: A1 |